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Abstract
Migraine is a common condition in which the diagnosis is based on clinical grounds. There is no clinically
available biophysical marker that can evaluate migraine. Migraines are linked to functional brain changes in
the absence of structural abnormalities. A clinically useful tool capable of evaluating functional changes in
patients with migraine could be used to aid diagnosis and management.
Patients with chronic migraine have frequent or continuous headache which is accompanied by significant
morbidity. There are limited data available regarding treatment options for curtailment of chronic migraine.
In this prospective observational study, patients suffering from chronic migraine underwent a prolonged
subcutaneous lignocaine and ketamine infusion which has anecdotally been useful in management of chronic
migraine. To determine if peripheral nerve excitability studies have a role in assessing patients with chronic
migraine and their response to treatment, these studies were performed on patients before, during and after
the infusion and at six months and compared to healthy age matched controls.
Most patients (13/14) had significant clinical benefit from the infusion. No changes in excitability studies
were identified in patients at baseline, during or after intervention with low-dose lignocaine/ketamine
infusion. The lack of detectable change in excitability measurements despite significant clinical improvement
resulting from the infusion may implicate a central mechanism of action of the infusion.
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CHAPTER

1

1.1 Headache
Headache is a general term for the sensation of pain in the head region. The location of pain can
vary greatly between individuals, with some headaches being isolated to certain regions while others
are bilateral across the head. A headache may be described as a sharp pain, a throbbing sensation
or a dull ache. Headaches can develop gradually or suddenly with the duration varying from less
than an hour to several days.
Headache is a symptom, rather than a diagnosis. The clinical symptoms allow identification of
underlying cause and direct treatment. Hence, an understanding of how underlying headache
patterns are classified is imperative for patient care. While additional neurological tests may assist
in the exclusion of some pathologies, headache requires clinical interpretation.
Different headache patterns may co-exist concurrently within an individual. For example it is
common for frequent episodic tension-type headache to coexist with migraine without aura. It can
be difficult to differentiate between some headache disorders.
The International Classification of Headache Disorders (ICHD-III) classifies headaches into either
primary or secondary based on the pathophysiology (Headache classification Committee, 2018).
The classification of the 14 types of headache is summarized in table 1.1.
A primary headache refers to a disorder generated by primary pathophysiology affecting the cranial
structures which is not caused by other medical conditions. Secondary headache is the term given
to headaches in which an underlying cause is found such as trauma, tumour, infection and metabolic
disorders.
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This thesis focuses on primary headache disorders, specifically those patients who have developed
chronic migraine (CM) with or without medication overuse. This focus reflects the common
presentation of migraine and CM patients in neurological practice.
Table 1.1: Summary of IHS Classification of headaches*
Primary Headache

Secondary Headaches

Other



Migraine







Tension type headache (TTH)



Trigeminal autonomic

or injury


Other Primary headache

Cranial neuropathies, other
facial pains

Headache attributed to cranial



other headaches

or cervical vascular disorder

cephalalgias


Headache attributed to trauma



Headache attributed to nonvascular intracranial disorder

disorders


Headache attributed to a
substance or its withdrawal



Headache attributed to
infection



Headache attributed to disorder
of homoeostasis



Headache or facial pain
attributed to disorder of the
cranium/neck/eyes/ears/nose/
sinuses/ teeth/ mouth or other
facial or cervical structure



Headache attributed to
psychiatric disorder

*Headache classification Committee, 2018
1.1.1 Migraine diagnosis
Migraine is a recurrent disorder characterised by moderate to severe episodic headaches. Typical
features are lateralised headache, 4-72 hours duration, and pulsating nature, aggravation by routine
physical activity, generally associated with nausea, photophobia and phonophobia.
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Migraine may be associated with aura (MA), which is a transient phenomenon of disturbed
sensory perception. This may occur without headache (acephalic migraine). Aura symptoms are
fully reversible symptoms and may include alterations to visual, sensory, speech, motor, brainstem
and retinal vision. Up to 38% of patients with migraine have attacks with aura which usually occur
before pain phase of the headache and may continue into the pain phase (Kelman, 2004). Visual
aura is most common, occurring in over 90% of migraine with aura individuals.
Table 1.2 Diagnosis criteria for migraine per ICHD-III criteria *
Migraine without Aura (MO)
Diagnostic

1.

Criteria

Migraine with Aura

At least 5 attacks meeting the

1.

criteria 2-4

At least 2 attacks meeting the criteria 23

2.

Headache lasts between 4-72 hours

3.

Headache has at least two of the

changes in aura symptoms:

following:

- Visual

- Lateralised

- Sensory

- Pulsating quality

- Speech and or language

- Moderate or severe pain

- Motor

- Aggravation by or avoidance of

- Brainstem

routine activity

- Retinal

4.

5.

During headache there is at least

2.

3.

One or more of the following reversible

At least three of the following aura

one of following

symptom:

- Nausea and or vomiting

- at least one aura symptom spreads

- Photophobia and phonophobia

gradually over ≥ 5 minutes

Not better accounted by another

- two or more aura symptoms occur in

ICHD-3 diagnosis

succession
- each individual aura symptom lasts 560 minutes
- at least one aura symptom is unilateral
- at least one aura symptom is positive
- the aura is accompanied, or followed
within 60 minutes, by headache
4.

Not better accounted by another ICHD3 diagnosis

*Adapted from International Classification of Headache Disorders III, Headache Classification
Committee, 2018
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1.1.2 Medication overuse headache diagnosis
Medication overuse headache (MOH), previously known as “analgesic rebound” headache, is a
recurring headache induced by repetitive and chronic overuse of acute headache medication. It is
perpetuated by the frequent use of short acting analgesics where headache will develop after a
short predicable time as medication levels fall.
MOH may escalate as a vicious cycle and develop when analgesics are taken an increasing
frequency to alleviate the increased headache frequency.
The diagnostic criteria have updated in ICHD III definitions to be i) headaches that occurs at least
15 days per month in individuals with a pre-existing headache disorder while ii) regularly
overusing medication for at least three consecutive months. ICHD III criteria brings MOH criteria
into alignment with CM criteria and reflect the common dual clinical presentation.
MOH is typically seen in migraine and tension type headache (TTH) patients who use triptans,
ergots, opioids and other analgesics where intake occurs on 10 or more days per month. Triptans
tend to produce MOH more rapidly than either ergots or analgesics.
Management of the rebound cycle requires removal of the offending medication and withdrawal
symptoms occurs with varying severity.
1.1.3 Chronic migraine
Chronic migraine (CM) also referred to as “transformed” migraine is defined by experiencing at
least 15 headache days per month, which at least eight meet migraine diagnosis (Section 1.1.1), for
at least three consecutive months.
In most cases, patients with CM have a history of occasional primary headache, increasing in
frequency over months to years. This is common in MOH patients where overusing pain
medications is a common behaviour in patients with CM. A patient can be classified as having CM
together with MOH.
This sub-population of headache patients has a greater burden of disease and may be more
refractory to conventional care, compared with other headache patients. The additional diagnosis
4

of CM in patients with MO or MA is important as it may reflect underlying pathophysiological
changes.
1.1.4 Migraine epidemiology
Migraine is considered to be the world’s third most prevalent disorder (Vos et al., 2010).
Prevalence rates differ with age, gender and ethnicity (Bigal et al., 2010; Bigal et al., 2006).
Prevalence
The prevalence of migraine is assumed to be relatively stable over the last 3 decades (Table 1.3).
Table 1.3 Comparison of three largest US migraine populations over time
Study

Year

Migraine Prevalence %
(Male/Female)

American Migraine Study

1989

12.1 (5.7/ 17.6)

1999

12.6 (6.5/ 18.2)

2004

11.7 (5.6/ 17.1)

(Steward et al., 1992)
American Migraine Study II
(Lipton et al., 2001)
American Migraine Prevalence and Prevention
(Lipton et al., 2007)

Age
The prevalence of migraine changes with age. Migraine occurs in 3–10 % of pre-pubertal children,
and the rates are similar among boys and girls. During adulthood prevalence increases to 11-13%
with peak prevalence in both genders in the 30–39 age bracket. Prevalence declines in
postmenopausal women. (Figure 1.1.)
Symptom patterns may vary with age and individuals under 18 years present with more bilateral
pain than adults.
Gender
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Worldwide prevalence data from the 2015 Global Burden of Disease Study show that migraine
affects close to three times as many adult women (15–17 %) as adult men (6 %) with a strong
correlation between childbearing age and prevalence (Global Burden of Disease, 2015).
Migraine severity is also affected by gender with women more likely to experience more intense
migraine than men.

Figure 1.1 Global burden of disease 2015 point prevalence of migraine in men and women.
(Image adapted from Vetvik KG and MacGregor EA, 2016)

Ethnicity and Genetics
There are limited studies directly comparing ethnicity. However, there are strong genetic links in
migraine. Approximately 70% of migraine patients have a first-degree relative with a history of
migraine (Kors et al., 1999). The risk of migraine is increased 4-fold in relatives of people who
have migraine with aura.
6

Table 1.4 Comparison of migraine point prevalence by region (Table adapted from Stovner
et al., 2007)
Region

Overall Prevalence %

Male Prevalence %

Female Prevalence %

(Number of studies)

(Number of studies)

(Number of studies)

Africa

5 (5)

3 (4)

6 (4)

Asia

9 (8)

6 (8)

11 (8)

Europe

15 (14)

7 (13)

18 (14)

North America

13 (9)

6 (7)

18 (7)

Central/ South America

9 (10)

4 (10)

12 (10)

Global

11 (41)

6 (41)

14 (43)

Incidence.
The American Migraine Prevalence and Prevention (AMPP) study estimated an overall migraine
incidence of 8.1 per 1000 person–years (Lipton et al., 2001). A European study showed a peak
incidence at 20- to 24-years in females (18.2 per 1000 person–years), and at 15- to 19-years in
males (6.2 per 1000 person–years) (Lyngberg et al., 2005).
The number of new cases per year declines with age after a peak at 25- to 34-year-old females at
23 per 1000 person–years, and in males at about 10 per 1000 person–years. In the 55–64 years of
age group, the incidence was less than 5 per 1000 person–years (Lipton et al., 2001).
Migraine severity is greater in patients with more frequent episodes. The AMPP and CaMEO
studies have shown similar incidence and prevalence data comparing 2004 and 2014 (Lipton et al.,
2016).
Essentially, incidence changes with age, incidence is similar between US and Europe and
incidence rates have been stable over the last 20 years.
Economic burden/cost of disease
It has been reported that 90% of migraineurs have some headache-related disability, and
approximately half become severely disabled or require bed rest during an event (Global Burden
of Disease, 2015). Migraine can affect an individual’s social, personal and professional
7

performance. There are also large direct costs to health system with the cost of medication and a
significant investment of health care professional time to treat migraine.
Global Burden of Disease studies have classified migraine as the sixth highest cause of worldwide
years lost due to disability recent studies have indicated migraine is the third cause of disability in
under 50s (Global Burden of Disease, 2015). This estimates that migraine may reduce healthrelated quality of life to a similar degree as osteoarthritis or diabetes. The effects are augmented
because migraine effects are greater during the most productive years of life (Steiner et al., 2016;
Steiner et al., 2018).
In 2016, the economic burden of migraine in the US was estimated to an annual per-person cost of
US $2649 for episodic migraine largely from absenteeism, decreased productivity and the cost of
treatment (Messali et al., 2016). The indirect cost of migraine to US employers is estimated at $13
billion annually. These may be underestimates since they do not consider unemployment or
underemployment related to migraine.
Socioeconomic Effects of migraine.
Some studies have shown an inverse relationship between the prevalence of migraine and
socioeconomic status (measured by income or education). Stewart et al. (2013) reported a higher
incidence in lower household income groups. However, other studies conflicting results and no
clear consensus has been reached (Lipton et al., 2002; Buse et al., 2012). These differences may
be a consequence of the barriers to good medical care in lower household income groups (defined
as medical consultation, accurate diagnosis and appropriate pharmacological treatment). As
migraine is undiagnosed or self-diagnosed and is largely self-treated. The barriers to good medical
care may be larger in lower household income groups.
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Comorbidity
Migraine is associated with multiple disease states and summarised in Table 1.5.
Table 1.5 Comorbidities of migraine (Adapted from Wang et al., 2010)
Epilepsy

Ischemic stroke

Chronic non headache pain

Coronary heart disease

Patent foramen ovale

Asthma/allergy

Mitral valve prolapse

Systemic lupus erythematosus

Sleep apnoea

Restless legs syndrome

Raynaud’s phenomenon

Sub-clinical vascular brain lesions

Psychiatric diseases (depression, anxiety, bipolar

Tourette syndrome

disorder, panic disorder, and suicide)

1.1.5 Migraine biomarker
There is no clinically useful migraine biomarker. This a challenge for clinicians as the sensation
of pain associated with migraines is subjective.

9

1.2 Migraine Physiology
Migraine initiation probably depends upon a complex relationship between genetic,
environmental, cognitive and emotive factors. The core underlying dysfunctions that ignite
migraine attacks probably involves both neuronal and vascular components including the cerebral
cortex, the brainstem, the thalamus and the peripheral and central components of the trigeminocervicovascular complex. Functional MRI and PET scans have demonstrated that that the
hypothalamus, the midbrain ventral tegmental area and the periaqueductal gray (PAG) are
activated in migraineurs even in the absence of pain (Schulte et al., 2017; Schulte et al., 2016).
The relative importance and the exact sequence of activation of these structures during a migraine
attack are not fully understood and are under investigation.
There are likely pathophysiological differences between headache subtypes with peripheral pain
mechanisms associated with episodic subtypes and central mechanism associated with the
formation of chronic patterns. Structural changes including reduced gray matter in pain circuits
have been reported in headache patients especially in the anterior cingulate, amygdala and
operculum (Goadsby et al., 2017; Jia Z and Yu S, 2017; Goadsby PJ, 2015). Increased cortical
thickness for somatotopical representation of the head and face in the cortex has been noted in
high frequency chronic migraineurs compared to controls suggesting alterations in cellular
structure which may render cortical cells more excitable. This increase in cortical thickness in
migraine may result from a plastic reaction to repetitive pain processing (Hadjikhani N, 2008;
Spenger T and Borsook D, 2012; Da Silva et al., 2007).
Functional MRI studies have identified significant hypothalamic involvement in the aura and acute
pain phases of migraine. May (2017) identified a particular patient who was scanned on a daily
basis over a month to monitor three spontaneous untreated headache attacks. He demonstrated
hypothalamic activation in the prodromal phase (up to 24 hours before the onset of headache)
compared with the interictal state. Pain related hypothalamic functional connections between the
hypothalamus and the spinal trigeminal nuclei was significantly increased in the prodromal phase,
strongly suggesting that the hypothalamus plays a generating role in the development of migraine
symptoms.
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The following section will outline four theories: neurotransmitter, neurovascular, cortical
spreading depression and vascular.

1.2.1 Neurotransmitter hypotheses
This theory suggests that migraine originates from altered processing and release of
neurotransmitters. Implicated in the pathogenesis of migraine are substance P, neurokinin A,
calcitonin gene-related peptide, serotonin and nitric oxide which interact with the blood vessel
wall to produce dilation, protein extravasation, and inflammation. Plasma extravasation may not
be sufficient by itself to cause pain, in the presence of other stimulators it may be a critical step in
migraine development.
Some medications that are effective for migraine inhibit neurogenic plasma extravasation,
however, substance P antagonists and the endothelin antagonist bosentan inhibit neurogenic
plasma extravasation but are ineffective as anti-migraine drugs. As well as activation of
nociceptors in pain-producing intracranial structures the pain process also requires a reduction in
the normal functioning of endogenous pain-control gate pathways.
1.2.2 Neurovascular theory
This theory postulates that migraine is primarily a neurogenic process where the release of
neuropeptides from trigeminal nerve activation generates inflammation and pain. This produces
sensitisation of primary afferent neurons that innervate the cranial meninges that further increases
susceptibility to a future attack. This differs from previous theories where cranial vasodilation is a
result of activation of trigeminal nerves and not the cause.
Pain associated with migraine is thought to be a result of the activation of the trigeminovascular
system that consists of the neurons innervating the cerebral vessels whose cell bodies are located
in the trigeminal ganglion. This system makes synaptic connections particularly with painproducing large cranial vessels and dura and centrally projecting fibres synapsing on neurons in
the caudal brain stem and high cervical cord. This will mediate the release of vasoactive peptides
during a headache to activate pain pathways through a relay in the trigeminocervical complex.
This produces the severe and throbbing nature of pain.
11

Transcranial magnetic stimulation and functional magnetic resonance imaging of the migraine
patients at baseline confirms cortical activation as migraine evolves. This observation may explain
the susceptibility of the migrainous brain to headache. Stimulation of the greater occipital nerve
also causes neuronal activation in the same regions and enhances convergent inputs from the dural
vasculature (Strassman et al., 1996).
It is suggested dysfunction of sensory processing plays a pivotal role for increased perception of
pain and may explain the associated autonomic symptoms via ascending and descending pathways
in the brain.
1.2.3 Cortical spreading depression
Cortical spreading depression (CSD) is a generally accepted theory to explain migraine aura. CSD
a slowly propagating wave of depolarization followed by suppression of neuronal activity. It is
initiated in the occipital region of the cerebral cortex and is propagated towards the front of the
brain at 3-5 mm/ minute. CSD leads to the release of inflammatory mediators that alter
nociceptors, irritate trigeminal nerve roots and change cerebral blood patterns.
Although CSD can be easily investigated in experimental animals and in humans, using functional
magnetic resonance imaging, Hadjikhani (2008) was able to detect local increases in blood oxygen
level dependent signals that spread through the visual cortex of a patient with MA which is similar
to animal models.
The potential relationship between cortical spreading depression and migraine without aura
remains controversial. It has been suggested that the long-term release of inflammatory mediators
may structurally alter pathways and alter the processing of sensory inputs which alters disease
progression.
1.2.4 Vascular spasm hypothesis
Willis first suggested that migraine is a vasospastic disorder of the cranial vessels (Willis T and
Pordage S, 1683). Subsequently Wolff, supported that ischemia induced by intracranial
vasoconstriction is responsible for the aura of migraine and that the subsequent vasodilation and
12

activation of perivascular nociceptive nerves resulted in headache. New imaging technologies have
shown that intracranial blood flow patterns are inconsistent with this theory (Goadsby PJ, 2015).
Furthermore, this theory does not explain why some effective migraine treatments do not affect
blood vessels (Goadsby PJ, 2015).
1.2.5 Genetic causes of migraine (ion channel disorders)
Evidence for a genetic component in migraine comes from observational studies, which show that
approximately half of migraineurs have an affected first-degree relative. While genetic
determinants are seen as important, migraine risk is conferred by the complex interplay between
predisposing and triggering factors.
Insights into the genetic and molecular pathophysiology of migraine have come from studies of
rare monogenic subtypes of migraine, including dominantly inherited familial hemiplegic migraine
(FHM) and migraine in familial advanced sleep phase syndrome FASPS). FHM is characterized
by reversible hemiparesis plus other aura symptoms preceding or accompanying a migraine
headache with at least one first-degree relative similarly affected. Many of the features of
monogenic subtypes of migraine (e.g. hemiplegia during aura, progressive ataxia in FHM and
FASP) are not found in common types of migraine (Montagna P, 2000).
1.2.6 Triggers
Migraine attacks are generally spontaneous but some individuals have known triggers which vary
from individual to individual and will not always initiate a migraine. The mechanisms by which
migraine triggers exert their effect is not clear despite a large number of trigger factors reported
(Table 1.5). Furthermore, clinical studies investigating links between triggers migraine attacks
have shown conflicting results (Hoffman J and Recober A, 2013; Lippi et al., 2014).
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Table 1.6 List of common triggers
Stress

Dehydration

Emotion

Odours /Smoking

Hypoglycaemia

Alcohol

Altered sleep patterns

Caffeine

Physical exertion

Food chemicals (? Chocolate, MSG, nitrates)

1.3 Migraine Management
There are multiple approaches to manage the effects of migraine. It falls into two general types of
approaches, a pharmacological and a non-pharmacological approach. There are wide array of
pharmacological options that either aim to minimise the symptomatic effects or to act as a
migraine prophylaxis.
1.3.1 Symptomatic
Table 1.7 outlines commonly used pharmacological agents used in the symptomatic treatment of
migraines. The level of evidence varies greatly between commonly used agents and there are
multiple physiological targets, highlighting the complex and heterogenous nature of migraines.
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Table 1.7 Level of evidence of symptomatic migraine treatment
(Marmura et al., 2015; Schug et al., 2015).
Evidence

Pharmacological agent

Target

Level A

Triptans

Serotonin receptors

dihydroergotamine

Serotoninergic & adrenergic receptors 5-HT1D
receptors

(nasal spray)

Level B

Level C

NSAIDS

Cox 1 & 2

opioids

µ receptors

acetaminophen/aspirin/caffeine

Unknown. Postulated central effect and
prostaglandin inhibition

Ergotamine

Serotoninergic & adrenergic receptors

Ketoprofen

Cyclooxygenase inhibition

Ketorolac (IV & IM)

Cyclooxygenase inhibition

magnesium (IV)

Unknown. Postulated to interfere with substance
P release

Dexamethasone IVI

Interleukin/CGRP & prostaglandin suppression

Methadone IMI

µ receptor

Codeine oral

µ receptor

1.3.2 Preventative therapy.
A number of guidelines have been established outlining the circumstances in which preventive
treatment for migraine is recommended. These guidelines include:

15



Recurring migraine attacks that significantly interfere with a patient’s quality of life and
daily routine despite trigger management, appropriate use of acute medications, and
lifestyle modification strategies



Frequent headaches (four or more attacks per month or eight or more headache days per
month) because of the risk of chronic migraine



Failure of, contraindication to, overuse of, or troublesome side effects from acute
medications



Patient preference, that is, the desire to have as few acute attacks as possible



Presence of certain migraine conditions: hemiplegic migraine; basilar migraine (now called
migraine with brainstem aura); frequent, prolonged, or uncomfortable aura symptoms; or
migrainous infarction (Silberstein et al., 2012).

1.3.3 Non-pharmacological approach
There is evidence for self-care measures that help ease the frequency and intensity of migraine
including:


Avoidance of provoking factors, particularly alcohol and dehydration.



Physical therapy (including manual therapy, massage, muscle relaxation techniques,
meditation and yoga)



Sleep hygiene



Appropriate rest at headache onset



Maintenance of headache diary



Sensible application of alternative medicine techniques including:
o Acupuncture
o Biofeedback
o Cognitive behavioural therapy
o Herbs and vitamins (Shaik MM and Gan SH, 2015) .
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1.4 Nerve Excitability Studies
Physiological Background
The excitability of nerves is determined by the activity of a variety of ion channels, energydependent pumps, and ion exchange processes activated during the process of impulse conduction
(figure 1.2). Clinical symptoms can result from disorder of function rather than structure.
Therefore, tests of function are important investigatory tools for providing insights into disease
states.
Figure 1.2 Diagram of Node of Ranvier with ion channels

In myelinated nerves, salutatory impulse conduction occurs when the action potential (AP) jumps
from one node of Ranvier to the next. The traditional view of impulse propagation is that most
electrical activity develops at nodes of Ranvier, through specific Na+ and K+ channels and leakage
currents, whereas the internodal axolemma and myelin function as a passive isolated cable. In
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mammalian axons, the difference between internal to external voltages (resting membrane
potential) is modelled as approximately -84 mV (Howells et al., 2012). A nerve impulse is
generated as a result of the complex system of ionic pores changing between rest and activation.
Physiological states of depolarisation and hyperpolisation increase and decrease the ability of the
cell to generate a signal, respectively.
The main generator of a resting membrane potential is permeability to K+ ions and impermeability
to Na+ ions. Hyperpolarisation-activated cyclic nucleotide-gated (HCN) channels allow for the
passage of both Na+ and K+ ions and are most active at a range of -50 mV to -100 mV. This
function may limit excessive hyperpolarisation mediated via Na+/ K+ pump activation from
excessive impulses or from ischaemia.

Nerve Excitability Studies
Currently, nerve conduction studies (NCS) are the mainstay of studying peripheral nerve function
clinically. NCS use supramaximal stimuli to generate an action potential and measure velocity
and amplitude of large myelinated motor or sensory fibre conduction, which are largely functions
of nodal saltatory conduction. Nerve excitability studies (NES) are a non-invasive in vivo research
tools used to investigate nerve function. In contrast to nerve conduction studies, NES use much
smaller stimuli designed to just excite the nerve at its threshold. Nerve excitability studies involve
applying a series of priming stimuli to the nerve before the test, and then track the resultant change
in threshold to indirectly evaluate membrane potential and ion channel function. Hence nerve
excitability studies provide complimentary information to NCS.
NES use a TROND protocol as described by Kiernan et al., (2000). The TROND protocol
consists of a series of conditioning stimuli delivered via constant current stimulators and response
signals displayed, analysed and recorded using QTRAC (copyright Institute of Neurology,
London) software written by Professor Hugh Bostock. (Test stimulus combinations explained in
sections 1.4.2 to 1.4.6.)
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1.4.1 Threshold Tracking Principle
The principle of threshold tracking is illustrated in figure 1.3. This depicts a test pulse along a
nerve and the elicited muscle response below (A). If a conditioning depolarising electronic pulse
is added, the test pulse produces a supra maximal response (B). Test response A can be elicited by
applying a conditioning stimulus with a reduced test pulse (C). Threshold change when the
muscles response is the same is the difference between the control threshold and the conditioned
threshold expressed as a percentage of initial stimulus.

Figure 1.3 Threshold tracking representation
A

B

C

(Adapted from TROND nerve excitability workshop Chicheley 2015 )

1.4.2 Stimulus response curve
A stimulus response curve is constructed from stimuli increasing in small increments to supramaximal responses using a 0.2 ms pulse duration. A threshold current is then deﬁned for tracking
purposes as the stimulus strength required to elicit a 40% maximal response. The magnitude of
changes in stimulus intensity is determined from the stimulus response curve and are automatically
calculated by QTRAC-S software.
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1.4.3 Strength duration relationship
The strength-duration relationship is plotted by adjusting the duration of the rectangular
stimulating current pulse (Figure 1.4). The threshold or stimulus strength required to elicit the
desired (40% maximal) response is obtained via threshold tracking for each time point. The
threshold is measured at five different pulse widths from 0.2 to 1.0 ms, and the threshold charge is
plotted against stimulus duration. The derived charge duration plots provide the measurements of
strength-duration time constant (STDC) and the rheobase.

Figure 1.4 Multiple pulse widths used in Strength duration plots

(Adapted from TROND nerve excitability workshop Chicheley 2015 )
1.4.4 Threshold Electrotonus
Threshold electrotonus (TE) is a measurement of threshold changes as a result of sub-threshold
conditioning stimuli (Figures 1.5 and 1.6).
Conditioning currents of +20% and +40% (depolarising) and -20%, -40%, -70% and -100%
(hyper-polarising) of control threshold were chosen. The threshold change was chosen at 26 time
points that were before, during and after the conditioning stimuli.
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Figure 1.5 Depolarising condition used in threshold electrotonus

(Adapted from TROND nerve excitability workshop Chicheley 2015 )

Figure 1.6 Hyper-polarising condition used in threshold electrotonus

(Adapted from TROND nerve excitability workshop Chicheley 2015 )
1.4.5 Recovery Cycle
The recovery cycle is measured by using a supramaximal conditioning stimulus followed by a test
stimulus at varying conditioning-test intervals from 2 to 200 ms. This test creates three distinct
periods: refractory, super-excitable and sub-excitable period.
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The refractory period is determined by inactivation of the Na+ channel gate on the internal aspect
of fast Na+ ion channels. The absolute refractory period corresponds to the closure of these
inactivation gates and the relative refectory period is the period of time to recovery from
inactivation to the opening of the in-activation gates.
The super-excitable period reflects the depolarising after potential, which is a result of capacitance
charging at the internode. This is also known as Barrett and Barrett current. The Barrett and
Barrett current discharges through or under the myelin sheath is dependent on membrane potential
(Barrett and Barrett, 1982).
The sub-excitability period reflects hyper-polarising effects of inactivation of slow K + channels
from the conditioning stimuli. This period is dependent on membrane potential and also the
electrochemical gradient of K+ ions.
1.4.6 Current Voltage Relationship
This relationship is analogous to threshold electrotonus while utilizing a fixed 200 ms conditioning
current that varies in steps of 10% from +50% (depolarising) to -100% (hyperpolarising) of
threshold. The change in threshold reflects the rectifying properties of the axon, specifically the
properties of K+ channels and hyperpolarisation-activated inwardly rectifying currents (Ih).
1.4.7 Nerve excitability studies and migraine
The scientific rational is described in detail in chapters three. A brief synopsis is outlined below.
Chronic migraine has a heterogenous pathophysiology theorised as aberrant peripheral and central
hyperexcitability of pain pathways leading to a dysregulation of sensory perception. Many
migraine treatments, including anti-epileptic agents act via alterations in resting membrane
potential or possibly by altering central ion channel function.
In addition to documenting changes in membrane potential in a wide number of conditions
affecting peripheral nerve, excitability studies have been able to identify changes in membrane
potential in peripheral axons in selected CNS disorders (e.g. stroke, multiple sclerosis, spinal cord
injury), probably reflecting compensatory altered regulation of ion channel expression in these
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disorders (Krishnan et al., 2009; Tomlinson et al., 2018). Hence, in a heterogeneous population
of chronic migraine patients, where the symptoms may be the nett effect of centrally and
peripherally acting processes affecting nerve excitability, it could be hypothesised that changes in
peripheral nerve excitability studies may reflect this nett effect of central and peripheral activity.

The use of NES to detect changes in peripheral nerve excitability reflecting disorders a central
function is well established (Tomlinson et al., 2009; Tomlinson et al., 2016; Tomlinson et al.,
2018; Krishnan et al., 2009). This has laid the groundwork to apply similar principles to common
conditions such as chronic migraine in which the physiology is not completely understood.
To date, there are no studies that have specifically investigated nerve excitability in human
migraine. Considering that migraine’s pathophysiology is consistent with neurovascular theory
with neuronal hyperexcitability, it is hypothesised that NES can be used as a research tool to
provide insights into this disease state.
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1.5 Evaluating a lignocaine and ketamine subcutaneous protocol in a chronic migraine population
and search for a novel biomarker
The presentation of chronic migraine is a frequent occurrence in neurological practises. It is can
be challenging to manage these patients as there are limited therapeutic options and an incomplete
understanding of chronic migraine physiology. More neurophysiological research into chronic
migraine is required to meet this unmet need.

1.5.1 Study Proposal
The studies in this thesis aim to evaluate the effectiveness of a protocol used in the treatment of
chronic migraine and to investigate potential new objective markers for treatments. The specific
research questions addressed are:
1. Does the use of subcutaneous lignocaine and ketamine infusion protocol in chronic
migraine translate to improved clinical outcomes by subjective measures?
There is no reported information on the use of low dose combined subcutaneous lignocaine and
ketamine infusion in a refractory chronic migraine population. Clinicians at St Vincent’s Private
Hospital (Sydney) have employed this protocol in the treatment of refractory chronic migraine
based on similar reported protocols using intravenous lignocaine in headache patients. To date, the
effect on subjective headache markers resulting from differences in i) combination with low dose
ketamine and ii) administration through different routes, have been anecdotal.
2. Can nerve excitability studies be used as a clinical tool to provide in vivo assessment of the
treatment?
The therapeutic action of some migraine treatments results from alteration of ion channel function
and nerve excitability. Lignocaine’s therapeutic benefits on pain is reported to relate to changes
in sodium channel function. Therefore an in vivo assessment of ion channel function may reflect
differences and provide an objective marker of this treatment. A biomarker of treatment would
provide clinicians with greater information on how best to direct treatment.
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Nerve excitability studies are research techniques that demonstrate in vivo peripheral excitability
changes as result of ion channel mutations and from high dose lignocaine administration. Episodic
Ataxia type 2, which is allelic with familial hemiplegic migraine, also has reported peripheral
nerve excitability differences from normal subjects. Therefore, nerve excitability studies in chronic
migraine may therefore identify a new biomarker where there are currently no clinically useful
surrogate markers of migraine intensity or activity.

1.5.2 Aims
1. To evaluate the effectiveness of continuous (7-10 days) subcutaneous lignocaine and
ketamine infusion for treatment of chronic migraine with regards to frequency and severity
of migraine, lost days of productivity and amount of headache medication required.
2. To obtain peripheral nerve excitability studies in patients with chronic migraine before,
during and after treatment with a lignocaine and ketamine infusion to develop an in vivo
biophysical marker of change of neuronal hypersensitivity in these patients with treatment,
as well as an objective measurement of lignocaine effect during infusion.
1.5.3 Hypothesis
We hypothesise that a continuous subcutaneous lignocaine and ketamine infusion will decrease the
frequency and severity of migraines and improved productivity of participants.
We hypothesise that nerve excitability studies may detect changes in peripheral nerve ion channel
function before and after treatment that may provide a useful predictive biomarker of migraine and
treatment responses.
1.5.4 Study design
A prospective observational cohort study, designed to observe the outcome of a patient’s
management as determined by their treating neurologist. The study was not designed to direct or
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alter therapy, rather follow the course of their individualised care before and after inpatient
intervention.
Patients were considered eligible for inclusion if:
a) Chronic migraine diagnosis was confirmed by the treating neurologist according to ICHD-3 β
criteria
b) patients were refractory to standard therapies
c) aged between 18-70.
Patients with known contraindications to the therapy including prolonged QT interval on ECG or
malignant arrhythmia were excluded from the study.
Patients underwent evaluation at four-time points including clinical assessment, headache diary
review, MIDAS questionnaire (migraine disability assessment score), medication review and nerve
excitability studies (See Figure 1.7 Summary of Procedures for Observational Study of
Management of Chronic Migraine and Table 1.7 Schedule of Events).
More specific information is outlined in methodology section in Chapters two and three.
Table 1.8 Schedule of events
Visit 1
(Baseline)

Medical History

Visit 2

Visit 3
(admission day 5)

(admission)

Visit 4
(90 days)

Visit 5
(180 days)

X

and consent
MIDAS
Medication

X

X

X

X

X

X

X

X

X

X

X

Provided

X

X

X

review
Nerve

X

excitability
studies
Headache diary
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Figure 1.7 Summary of Procedures for Observational Study of Management of Chronic
Migraine
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1.5.5 Study procedures
The following outlines the specific information that was collected:
Medical History
A clinical assessment and medical history were obtained (appendix 7). This included a
comprehensive migraine history, medications used for migraine, clinical exam, social and family
history.
MIDAS
Migraine disability assessment (MIDAS) is a scale that gives clinicians a measurement of impact
of headaches on daily activity. See appendix 4.
Medication Review
Participants were asked to record medications used for migraine management.
Nerve Excitability Studies
Tests were performed on the participant’s median nerve with six surface electrodes (per Figure 2
set up). Compound action potentials were recorded along the abductor pollicis brevis after
stimulation of the median nerve near the wrist. Current was delivered from DS5 stimulators
(Digitimer Ltd, UK) and QtracS stimulation software following the TRONDNF protocol. Nerve
Excitability tests were performed prior, during and after the infusion.
Headache Diary
Each was requested to keep a detailed headache diary that included number of headache episodes,
pain scores, medication used and other associated factors including menstrual periods. See
appendix 5.
Infusion protocol
A preparation containing lignocaine, ketamine and saline was delivered subcutaneously to the
patient via a syringe driver and butterfly cannula to the lateral abdominal wall or outer thigh. The
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rate of infusion was slowly titrated over the first 24 hours and adjusted as clinically indicated by
the headache response. The patients were regularly monitored for pain, sedation and adverse
effects with rotation of subcutaneous infusion site. While in hospital, they engaged in regular
consultation and create an appropriate management plan.
The infusion protocol was initiated on Visit 2 (admission) per scheduled of events (Table 1.8).
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1.5.6 Treatment rationale

The scientific rational of the treatment is described in detail in chapters two. A brief synopsis of
study rational is outlined below.
There are limited published data suggesting benefit from administration of intravenous lignocaine
for treatment of MOH and CM (Hand and Stark, 2000; Rosen et al., 2009). Lignocaine blocks the
activation of voltage-gated Na+, preventing depolarisation of the post-synaptic membrane and
propagation of the action potential. Its short half-life and duration of action necessitates continuous
parenteral infusion. The efficacy of lignocaine in treatment of chronic migraine probably relates to
reduction of neurally-driven pain in both the central nervous system and also in peripheral
trigeminal nociceptive afferents.
The use of parenteral ketamine in chronic pain and neuropathic pain is well documented
(Kvarnstrom et al., 2003; Campbell-Fleming et al., 2008), including some reports of response in
chronic headache (Webster and Walker, 2006). Intranasal ketamine has been studied in acute
migraine and may reduce severity but not duration of migrainous aura (Afridi et al., 2013). Short
term improvement in chronic migraine severity has been shown with use of intravenous ketamine
in a small case series of six (Lausisten et al.,2016).
Ketamine decreases central sensitization and allodynia (Sanchez-Porras R et al., 2014), possibly
due to reduction activation of pain processing pathways including decreased activation of the
secondary somatosensory cortex, insula and anterior cingulate cortex (Sprenger T et al., 2006). It
is thus a suitable agent for chronic migraine treatment.
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Abstract
The entrenchment of chronic migraine, often compounded by analgesic dependence and
perpetuated by recognized barriers to treatment. This report describes an approach to treatment
which includes admission to hospital for administration of a low dose subcutaneous lignocaine and
ketamine infusion. The aim is to enable adequate analgesia and disruption of entrenched headache
while patients undergo revision of oral medications and implementation of non-pharmacological
strategies to treat chronic headache. Fourteen patients were recruited, nine of whom were female.
Mean age was 43 years (range 27-61). The infusion was tolerated without significant side-effects.
At six months, 13/14 patients had sustained benefit from admission. Three of 4 patients remained
free of MOH headache. One patient remained headache-free at six month follow up. Conversion
from chronic migraine to episodic migraine was seen in 6/14. Improvement in chronicity was
reported by 6/14. Two of six patients unable to work because of chronic headache were able to
return to work, and a third patient returned to studies. These findings suggest that a prolonged
subcutaneous lignocaine and ketamine infusion is a useful adjunct to conventional management to
enable breaking the entrenchment of chronic headache with.
Key words:

chronic migraine, migraine, lignocaine, ketamine, medication overuse

headache
Abbreviations:

NSAIDS: Non steroidal anti inflammatory drugs
ICHD-3: International Classification of Headache Disorders version 3
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Introduction

The management of chronic migraine includes correcting medication overuse headache and
implementing suitable preventative agents and appropriate use of medications for acute episodes
(May and Schulte, 2016). However, in many cases this management paradigm oversimplifies the
complexity of chronic migraine and does not address the other factors that contribute to the cycle
of headache, particularly the central pathways that perpetuate chronic migraine. Abrupt
discontinuation of overused triptans and opioids may produce withdrawal symptoms
(Kristoffersen and Lundqvist, 2014) and patients with chronic migraine may experience major
escalation in headache while changing preventatives. The combination of headache intensification
and/or withdrawal side effects may sabotage implementation of a management plan, particularly
where the lead-in time of action of preventative medications may be days to weeks.
In an inpatient setting, chronic migraine patients are able to access adequate analgesia to minimize
impact of medication withdrawal and be provided with support and education to implement a
multifaceted management plan to address factors perpetuating their complex disability. In the long
term, with reduction in both direct and indirect costs, this option may prove both cost-effective and
more successful for those patients with recalcitrant headache.
While not first-line treatment, limited published data suggest benefit from inpatient administration
of intravenous lignocaine for curtailment of medication overuse headache and chronic
migraine(Hand and Stark, 2000; Rosen et al., 2009). Lignocaine blocks activation of voltagegated sodium channels, preventing depolarisation of the post-synaptic membrane and propagation
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of the action potential. Its short half-life and duration of action necessitates continuous parenteral
infusion in this setting. The efficacy of lignocaine in the treatment of chronic migraine probably
relates to reduction of neurally-driven pain in both the central nervous system and also in
peripheral trigeminal nociceptive afferents. The mean duration for positive results appears to be
8.5 days (Lake et al., 1993;Rosen et al., 2009) implicating that treatment duration is a factor in
‘resetting’ entrenched patterns of neurally-driven pain.
Ketamine is an agonist of N-methyl-D-aspartate (NMDA) receptors acting in the central nervous
system, and also has activity on opioid, monoaminergic, cholinergic, nicotinic, and muscarinic
receptors (Craven, 2007). In the setting of transformed migraine, it provides short-term analgesia
and enables reduction in central sensitisation of pain pathways, particularly in the setting of
codeine and opioid overuse (Goldberg et al., 2005; Tawfic QA, 2013). The use of parenteral
ketamine in chronic pain and neuropathic pain is well documented (Kvarnstrom et al., 2003;
Campbell-Fleming et al., 2008), with some reports including chronic headache in their cohort
(WebsterR and WalkerJ., 2006). Intranasal ketamine has been studied in acute migraine: it may
reduce the severity but not the duration of migrainous aura in the acute setting (Afridi et al., 2013).
Short term improvement in chronic migraine severity has been shown Pomeroy et al., 2017).
Ketamine decreases central sensitization and allodynia in pain conditions (Sanchez-Porras R et al.,
2014), possibly due to reduced activation of areas involved in nociceptive signals, the secondary
somatosensory cortex, insula and anterior cingulate cortex (Sprenger et al., 2006) thereby making
it a suitable candidate for chronic migraine treatment.
Intravenous use of these agents has various limitations: intravenous doses of lignocaine may cause
cardiac arrhythmias and administration may require cardiac monitoring. Ketamine may produce
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obtundation, dysphoria or hallucinations in higher doses. There are no published data regarding the
combination use of these medications in chronic migraine. This paper describes an inpatient
approach to management of patients with chronic migraine that includes supportive care of
symptoms with a prolonged subcutaneous lignocaine and ketamine infusion during
implementation of appropriate medication, along with a management plan to address concurrent
limiting comorbidities.
Methods
Study design
Ethics approval was obtained through St Vincent’s Hospital Human Research Ethics Committee
(HREC/15/SVH/356) and the University of Notre Dame Human Research Ethics Committee
(017044S). Written informed consent was obtained from participants. A prospective
observational cohort study was undertaken to document the outcome of a patient’s management as
determined by their treating neurologist. The study was not designed to direct or alter therapy; the
aim was to follow the course of their individualised care as determined by their treating
neurologist before and after inpatient intervention. Patients aged 18-70 were eligible for inclusion
if they had suffered chronic migraine which had been refractory to standard migraine therapies.
Exclusion criteria included pregnancy, breast feeding and known contraindications to the therapy
including prolonged QT interval on ECG or malignant arrhythmia.
Patients underwent evaluation at four-time points: baseline assessment (before commencement of
infusion), day 5 of infusion, 3 months after infusion and six months after infusion. Each
assessment included clinical assessment, headache diary review and medication review. Prior to
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commencement of the infusion, baseline ECG, full blood count, renal function and liver function
were measured.
Infusion protocol
A preparation containing 1g lignocaine and 250 mg ketamine was diluted in 0.9% sodium chloride
(normal saline) to a total volume of 24 ml. The infusion was administered by a registered nurse.
Continuous infusion was delivered subcutaneously via a syringe driver (the NIKI T34™ Syringe
Driver) and through a 22 gauge butterfly cannula to the subcutaneous tissue of the lateral
abdominal wall or outer thigh and secured by a large transparent adhesive dressing. The infusion
was commenced at a rate of 0.5 ml/hour and slowly titrated over the first 24 -48 hours according to
clinical response. An infusion rate of 1.0ml/hour was regarded as optimal, based on the
occasional development of dysphoria at higher doses but individual rates varied between
0.6ml/hour and 1.5ml/hour. Patients were regularly monitored for pain, sedation and adverse
effects. The solution was replenished daily, and the, needle and insertion site were then changed.
The Numerical Rating Scale (NRS) was used to score headache every four hours from 0 to 10 (10
being ‘worst possible pain’). The infusion continued until adequate analgesia was reached or nonefficacy was established, as determined by patient report and evaluation of the treating clinician.
Inpatient Management
Analgesics including opioids and triptans that might have contributed to headache cycle were
ceased. Expected rebound of severe headache during inpatient medication change was managed in
the short term with judicious use of low dose subcutaneous midazolam, morphine and
metoclopramide as required. All patients received education about chronic migraine management

36

with the importance of sleep, mood and fitness emphasized. Written management plans for acute
headache and chronic headache were provided.

Results
Baseline characteristics
Fourteen patients were recruited from the clinical practices of headache neurologists over a 16
month period (Table 1). Nine patients were women. The age range was 27 – 61 years (mean = 43
years). Four had concurrent MOH at or immediately prior to admission attributed to triptans
and/or codeine. Six patients had clinical depression and 3 had other pain syndromes. All patients
had previously received extensive conventional outpatient headache management and had failed
several first-line agents for prevention and acute headache. The most frequently prescribed
analgesics for acute headache were triptans (4/14), non steroidal anti inflammatory drugs
(NSAIDS) (4/14) and codeine (3/14). Several patients were not taking any abortive medications
due to inefficacy. The frequency of analgesic use varied greatly and generally had limited benefit.
All patients had been prescribed migraine prophylactic agents prior to treatment. Employment
was directly affected in 8/14 patients. Six patients had stopped working entirely due to headache
and 4 had reduced capacity to work. Five patients were not working for other reasons.
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Table 1: Patient Demographics
1

Patient

Age; Sex
57; M

2

51; M

3

42; M

Diagnoses at enrolment
Migraine
Medication overuse headache (codeine)*
Cervicogenic headache
Chronic migraine
Medication overuseheadache (codeine)*
Chronic migraine

Relevant comorbidities
Fungal sinusitis

4

41; F

Chronic migraine

Fibromyalgia
Trigeminal neuralgia
Depression

5

29; M

Chronic migraine

Depression, anxiety

6

43; F

Chronic axial pain

7

27; F

8

48; F

Chronic migraine
Medication overuseheadache (triptan)
Chronic migraine
Medication overuseheadache (codeine,
diazepam)*
Chronic migraine

9

61; F

10

58; M

Chronic migraine
Medication overuseheadache (triptan)
Chronic migraine

11

56; F

Chronic migraine

12

58; F

13

55; F

Chronic migraine
Medication overuseheadache (codeine, triptan)
Chronic migraine

14

29; F

Chronic migraine

Depression, post traumatic stress
disorder, Anxiety,
Polycystic kidney disease
Hypertension
Alcohol excess
Vertigo
Non epileptic seizures
Hemifacial spasm, Stroke
Epilepsy
Depression
Depression
Depression
Fibromyalgia

*analgesic contributing to headache discontinued prior to admission to hospital
Outcomes during inpatient stay
The infusion was well tolerated in all patients. The duration of infusion was 6 - 22 days (mean 11
days). Minor subcutaneous infusion site reactions were seen in some patients characterized by
erythema and mild induration. The reaction dissipated within a 1-2 days of re-siting the infusion.
No patient experienced altered consciousness, hallucinations or arrhythmia during the infusion.
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All patients underwent change of preventative medications during their inpatient stay. The most
frequently prescribed preventatives were lamotrigine, botulinum toxin, gabapentin and topiramate.
Outcomes at six months
Thirteen of 14 patients in a population of previously refractory chronic migraine patients treated
with subcutaneous lignocaine and ketamine infusion had improved headache and quality of life at
discharge and follow up. Seven patients were no longer classified as having chronic migraine,
with one being headache free (Table 2). Six patients had converted from chronic migraine to
episodic migraine and 6/14 reported significant improvement in their chronic migraine at six
months with subjective reduction in severity and frequency enabling increased circle of
engagement (see Table 2). MOH was addressed where relevant and 3 of 4 patients remained free
of MOH headache at six months.

One patient had no improvement at six months and this patient

had been unsuccessful at stopping daily triptan use (Patient 9). At six month follow up, only one
patient used opiates (long acting) for headache control (Patient 13). This patient had a history of
intolerance to tricyclic medications, and liver dysfunction precluded use of other alternatives.
NSAIDs and triptans were the most frequently prescribed abortive agents at follow up.
Suboccipital steroid/lignocaine injections were effective in aborting acute relapse headaches in
four patients who had limited benefit from oral NSAIDs and triptans (Appendix 1).
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Table 2: Outcome of treatment at 6 months follow up
Headache

Episodic

Improved

Return to

Lifestyle

Opiate use at

Triptan

free

migraine

chronic

vocation

change

6 months

overuse at six

only

migraine

Patient

months

1

No

No

Yes

Yes

Yes

No

No

2

No

Yes

N/A

N/A

Yes

No

No

3

No

No

Yes

N/A

Yes

N/A

N/A

4

No

Yes

N/A

Yes

Yes

N/A

N/A

5

No

No

Yes

No

Yes

N/A

N/A

6

No

Yes

N/A

N/A

Yes

No

No

7

No

Yes

N/A

Yes

Yes

N/A

N/A

8

No

Yes

N/A

No

Yes

N/A

N/A

9

No

No

No

N/A

No

No

Yes

10

Yes

N/A

N/A

Yes

Yes

N/A

N/A

11

No

No

Yes

No

Yes

N/A

N/A

12

No

No

Yes

Yes

Yes

N/A

N/A

13

No

Yes

N/A

No

No

Yes

N/A

14

No

No

Yes

Yes

Yes

No

N/A

N

1/14

6/14

6/14

6/14

13/14

1/14

1/14

%

7%

84%

84%

84%

93%

7%

7%

*N/A = not applicable
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Work engagement or lifestyle significantly improved in 6 patients. Two of six who had stopped
work for headache were able to return to work, with one other returning to studies. One patient
returned to full time work after having had reduced hours. One further patient was able to
undertake a strenuous holiday having been unable to for many years (reflecting improvement in
activity/engagement).
Discussion
Chronic migraine is a complex, disabling disorder that at times requires intensive efforts from both
the patient and the neurologist to manage. The cohort described in this paper reflects the
experience described in headache literature with concurrent mood disorders and disengagement
from work and other common activities. Chronic migraine was abolished in half the patients,
with six converting to episodic migraine. Quality of life improved in 13 of the 14 patients as
measured by return to vocational activities or increase engagement in lifestyle activities including
regular exercise.
The positive outcomes observed may be in part due to a reduction of sensitized central pain
pathways and peripheral trigeminal nociceptive afferent pathways (Kaube et al., 1994). Prior
studies on chronic pain using intravenous lignocaine or ketamine reported sustained benefits when
infusions were given for at least 4 days (Niesters et al., 2014; Lauritsen et al., 2016; Etchison et
al., 2017) Allodynia scores, an indicator of central sensitisation has been reported to decrease
following administration of intravenous ketamine (Sanchez-Porras R et al., 2014), . Ketamine is
well recognized to have benefit for major depressive disorder (McGirr et al., 2014, Anrade, 2017)
which is increased in prevalence in patients with chronic migraine. It is conceivable that improved
mood and outlook with ketamine used in this protocol facilitates engagement with migraine
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management. The mean length of stay in hospital was 11.5 days. This is similar to observations
from other studies between 8.5 and 13 days (Rosen et al. 2009. Lake, Saper & Hamel, 2009). The
length of time is suggestive that sustained pain reduction requires stabilization of the entrenched
mechanisms that perpetuate pain.
There is good evidence that withdrawal of medications responsible for medication overuse
headache is effective in reducing the frequency of chronic migraine headache frequency and
improving quality of life (Diener & Limmroth, 2004). Inpatient and outpatient treatments as well
as advice have each been shown to be beneficial to improving outcomes in chronic migraine
(Rossi et al., 2006). However, randomised control studies have shown no significant differences
when comparing inpatient versus outpatient management (Lai and Wang, 2016). Rossi et al. 2013
argued that inpatient withdrawal is more effective than outpatient management in complicated
medication-overuse headache patients. The current patient cohort was selected after failure to
respond to advice and outpatient management. If avoidance of admission to hospital for these
patients is financially-driven, this may in fact be counter-productive as the long-term benefit with
regards to reduction in direct and indirect costs with improved control may outweigh the cost of
admission. Inpatient treatment allows for the constant monitoring of medication intake and for
possible withdrawal symptoms. The hospital provides a safe environment for removal of
offending medications and to re-educate patients on risk of medication overuse.
Prophylactic medication combinations are designed with the hope of synergistic effects from
different mechanisms of action. The preventative medications used by this cohort are second-line
agents (Appendix 8) reflecting that multiple first-line agents have been unsuccessful due to
inefficacy or intolerability. In the current cohort, the preventative regimen was altered for each
participant, often with combinations of migraine prophylactic agents including riboflavin,
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magnesium and antidepressants. There is very limited evidence for the use of multiple versus
single prophylactic agents in headache management. An improved response to preventative
medications that had been previously tried post-infusion was identified in some patients and was
presumably the result of multiple factors. It is difficult to determine whether the infusion protocol
had a specific effect on regaining a response to medications and we assume that the observed
restored response is primarily due to a sufficient period away from analgesic medication. This
outcome suggests that there should be a greater role for planned drug rotation in the refractory
chronic migraine populations to address tolerance and diminishing therapeutic responses.
While long term benefits will be compounded by a number of variables, reducing pain pathway
sensitisation should be an initial step in changing the intractable pattern. By designing a treatment
protocol that aims to reduce pain signals, the chance of providing headache treatments to benefit
the patient will improve.
Lignocaine and ketamine do have potential for serious adverse side effects which therefore
necessitate inpatient treatment. These risks are minimised through the protocol’s use of minimal
doses, subcutaneous administration to minimise risk of inadvertent bolus doses, gradual dose
escalation based on participant response and constant monitoring. There were no serious adverse
effects observed in this prospective cohort. The study was limited by population bias to a highly
refractory migraine population who had received inadequate relief from standard treatments.
Furthermore, the study participants were a heterogeneous population with multiple comorbidities
and recruitment only occurred at one site. Lastly, there was no control group. However, this study
was deliberately designed as a proof of principle to enable furthermore rigorous studies to be
performed.
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Conclusion
This study provides pilot data that support the use of low dose subcutaneous lignocaine and
ketamine infusion in refractory chronic migraine populations. Future studies can use this as a
platform for randomized placebo controlled trial and investigate the role of central sensitisation in
the maintenance of chronic migraine, potentially allowing the development of novel treatments.
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Abstract
Pathophysiology of chronic migraine is postulated as sensitisation of trigemino-cervical pathways
and entrenchment of central pathways involved in migraine generation. There are no readily
available clinical biomarkers for migraine to serve as an objective marker of the condition. In this
study, the hypothesis that nerve excitability studies may be useful in assessment of chronic
migraine patients is explored. Peripheral nerve excitability studies are sensitive to changes in
active and passive properties of the axonal membrane and have been used extensively as a marker
of systemic alterations in nerve function. Fourteen patients with chronic migraine underwent
nerve excitability studies of median nerve on four occasions over six months. During this time,
their treatment included hospital admission for a subcutaneous lignocaine and ketamine infusion as
part of headache containment. Studies performed before, during and after the infusion did not
differ from control values despite therapeutic benefit during the infusion and afterwards. Lack of
detectable change in peripheral axonal excitability has significance in that it could be inferred to
suggest a more proximal mechanism of action of the lignocaine and ketamine infusion rather than
via peripheral trigeminal afferents. It is noteworthy that medications used by this cohort that could
potentially affect membrane potential do not affect peripheral axonal excitability studies.
Key words
Chronic migraine; lignocaine; ketamine; nerve excitability; threshold electrotonus
Introduction
The challenge in developing a biomarker for assessment and diagnosis of migraine partly lies in
the heterogeneity of pathophysiology between individuals and within an individual, and the
variable influence of triggers (including hormonal factors, sleep, mood, stressors etc). Both
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central and peripheral pathways are implicated in the development of migraine and it has been
hypothesised that a dysregulation of sensory processing involves activation and sensitisation of
trigemino-vascular and upper cervical pathways relaying to the brain stem and diencephalic nuclei
(Goadsby et al., 2017). Imaging, neurophysiologic and biochemical studies also implicate cortical
dysfunction and hyperexcitability and release of proinflammatory and pain cytokines in the
generation of migraine (Pietrobon, 2005; Pietrobon and Moskowitz, 2011). With repeated
stimulation of trigeminal fibres, chronic migraine may lead to structural and functional changes
which may include release of nociceptive neurotransmitters and upregulation of ion channels or
sensory receptors on pain nerve endings. (Burstein et al., 2004; Aoki and Francis, 2011). As a
result, peripheral afferents are sensitised and the lower threshold to firing promotes central
sensitization, (Dodick and Silberstein, 2006) of which cutaneous allodynia, is a clinical marker
(Burstein and Jakubowski, 2004).
Insight into the pathophysiology of migraine has been advanced by modalities that assess dynamic
brain function during migraine and interictally. Functional assessment of brain or nerve activity in
migraine would ideally lead to a useful biomarker of disease analogous to EEG in epilepsy or ECG
in cardiac assessment. Tools for functional migraine evaluation have included functional MRI
(fMRI), positron emission tomography (PET), blood oxygen level–dependent (BOLD) functional
magnetic resonance imaging and neurophysiologic assessment of cortical excitability
(magnetoencephalography (MEG)), magnetic suppression of perceptual accuracy (MSPA) and
transcranial magnetic stimulation (TMS). These studies have given insight into the
pathophysiology of migraine but have limited usefulness in the clinical sphere and have identified
physiologic differences between acute and chronic migraine.

52

Activation of central pathways in acute migraine is different from that in chronic migraine. For
example, PET studies show continuous overactivity in certain brain regions in chronic migraine
compared to overactivity limited to attacks in episodic migraine (Weiller et al., 1995; Afridi et al.,
2005). Functional MRI studies show a stronger connectivity in the pain matrix in chronic
migraine patients than episodic migraine patients (Lee et al., 2019), and alterations in connectivity
with the resting state with larger changes seen the higher the severity of the headache (Coppola et
al., 2019). Results from studies using MSPA and MEG reflect increase in cortical excitability in
patients with chronic migraine compared to those with episodic migraine (Aurora and Brin, 2017).
A role for nerve excitability studies in migraine?
In considering a relevant tool for clinical evaluation of migraine, the use of axonal excitability
studies in peripheral nerve was explored in this study (the technique is described in the methods
section below). Nerve excitability studies have been used in clinical research for over 20 years
(Kiernan et al., 2000; Krishnan et al., 2009; Tomlinson et al., 2018). With relevance to this
present study, nerve excitability studies have been shown to demonstrate changes in peripheral
nerve that reflect reduction in calcium channel function in patients with Episodic Ataxia Type 2
(EA2) in whom mutations are found in the presynaptic calcium channel Ca v2.1 (Tomlinson et al.,
2016). EA2 is allelic with Familial Hemiplegic Migraine (FHM); the channel affected in EA2 and
FHM is expressed both centrally and at the presynaptic neuromuscular junction. Although rare,
FHM as a disease model for migraine implicates ion channel dysfunction and aberrant nerve
excitability in the generation of migraine (Russell and Ducross, 2011). Nerve excitability studies
in patients with EA2 show increased electrical threshold and increased response to
hyperpolarisation and depolarising currents. This indicates an indirect effect of abnormal calcium
current fluxes during development with the production of a calcium ion channel mutation. In the
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heterogeneous population of chronic migraine patients studied in this paper, it would be expected
that changes in CNS ion channel function may produce downstream effects that can be measured
in ion channel populations in the peripheral nervous system but it would not be expected that
excitability studies would identify single-channel dysfunction or a pathognomonic biomarker of
chronic migraine. However, with the understanding that excitability studies have identified
changes in other chronic CNS disorders (key findings summarised in Table 1), it is a reasonable
expectation that peripheral nerve excitability studies may show the nett impact of a chronic
disorder in which altered regulation of nerve excitability is a component of the pathophysiology,
albeit a largely central effect.
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Table 1. Nerve Excitability findings in central nervous system disorders
Condition
GEFS+

1

due to

SCN1B mutations

Key findings

Reference

Alterations in peripheral motor axon excitability reflecting

Kiernan MC et al., 2005b

reduction in transient and persistent sodium channel
conductance.

Stroke

Modulation of HCN2 channel activity with reduction of Ih3

Jankelowitz et al., 2007

in motor nerves on the affected side
Spinal cord injury

Changes in excitability may reflect changes
in axonal structure and ion channel function.

Lin et al., 2007
Changes

were more pronounced when injuries were more clinically
severe.
Multiple sclerosis

11% increase in slow K+ channel activity in peripheral

Ng K et al., 2008

motor neurones
Spinal cord injury

Acute changes in motor nerve excitability below the level of

Boland et al., 2009

the lesion evolve over time. Brief improvement after
stabilisation is noted before regression suggesting plasticity
of expression or excitability as the injury evolves.
Parkinson’s

No change compared to control subjects

Jankelowitz SK and Burke D, 2012.

Episodic Ataxia

Cav2.1 dysfunction in episodic ataxia type 2 has effects on

Tomlinson SE et al., 2016

Type 2

axon excitability, which may reflect an indirect effect of

disease

abnormal calcium current fluxes during development.

1

GEFS+ = generalised epilepsy with febrile seizures plus

2

Hyperpolarisation activated, cyclin nucleotide gated ion channels

3

Ih = hyperpolarisation activated conductance

Use of subcutaneous lignocaine and ketamine in chronic migraine
Treatment paradigms for acute episodic migraine are well established (Becker WJ, 2015). The
benefits of preventative treatments for those with frequent episodic migraine is also well
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documented (Silberstein, 2015). Despite this, at least 3% of patients with episodic migraine will
convert to chronic migraine each year, with a prevalence of chronic migraine of 6.6% - 8.8% in the
migraine population (Lipton et al., 2007; Adams et al., 2015) and of 1-2% in the general
population (Buse et al., 2012); the latter figure being comparable to the prevalence of epilepsy in
the general population. These patients have the highest morbidity and are the hardest to treat, with
no consensus or clinical pathway for optimal treatment. The aim of treatment of chronic migraine
is to convert the headache to a more manageable episodic profile, rather than aiming to ‘cure’ the
patient of all headache. It is relevant therefore that the physiology of chronic migraine differs
from acute migraine and involves entrenchment of central pathways and a lower threshold of
trigeminovascular pathways to firing. With this in mind, the cohort of chronic migraine patients
studied in this paper underwent a prolonged subcutaneous infusion of lignocaine and ketamine to
arrest their chronic headache cycle.
Intravenous lignocaine has been shown to improve chronic migraine in patients with both migraine
and analgesic overuse headache (Hand and Stark, 2000). Duration of the infusion is a key factor
in long lasting benefit. Williams and Stark (2003) demonstrated a prolonged lignocaine infusion
(mean 8.7 days) aborted chronic headache in 90% and removed medication overuse headache in
97% at the end of treatment with benefit enduring at six months in 70% of patients. Lignocaine is
felt to stabilise excitable pathways and reduce the entrenchment of the headache cycle via sodium
channel blockade.
With specific relevance to this present study, nerve excitability studies have been used to
demonstrate sodium channel blockade in vivo. Moldovan et al. (2014), demonstrated a measurable
effect of a locally-targeted lignocaine block of peripheral nerve in vivo. Lignocaine was injected
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to cause local anaesthesia of the median nerve at the wrist and the nerve was then studied with
nerve conduction and nerve excitability studies. The lignocaine caused rapid and complete block
of motor axon conduction localized at the wrist. Within three hours, clinical assessment of power
of the abductor pollicis brevis muscle had returned to normal, as had median
motor nerve conduction. However, motor nerve excitability studies detected marked changes with
only partial recovery at six hours and full recovery at 24 hours, illustrating the enhanced sensitivity
of excitability studies in detecting changes of axonal excitability compared to nerve conduction
studies. Mathematical modelling of the excitability measurements attributed the changes not only
to reduction in the number of functioning voltage-gated sodium channels but also to a decrease of
passive membrane resistance and an increase of capacitance. Furthermore, axonal excitability
studies have been used to demonstrate sodium channel blockade in patients with acute tetrodotoxin
poisoning after puffer fish ingestion (Kiernan et al., 2005a), defining a distinctive pattern of
altered motor axons function with changes in nerve excitability reproduced in a mathematical
model by a twofold reduction in sodium permeability. Thus it is reasonable to expect that a
lignocaine infusion could produce a measurable effect on peripheral nerve.
The use of parenteral ketamine in chronic headache and migraine has shown at least short-term
improvement (Webster and Walker 2006; Lauritsen et al.,2016). With reference to the reduction
in central sensitization and allodynia with use of ketamine in pain conditions (Sanchez-Porras R et
al., 2014), the mechanism is possibly due to reduced activation of affective areas of the pain
processing pathways including decreased activation of the secondary somatosensory cortex, insula
and anterior cingulate cortex (Sprenger et al., 2006). Ketamine is an agonist of N-methyl-Daspartate (NMDA) receptors acting in the central nervous system (Craven, 2007) and in the
protocol described below, ketamine provides adequate analgesia for the patient while modifying
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oral medications (i.e. removing agents causative of medication overuse and introducing
appropriate preventatives).
Methods
Study design
Approval for the study was obtained through St Vincent’s Hospital Human Research Ethics
Committee (HREC/15/SVH/356) and the University of Notre Dame Human Research Ethics
Committee (017044S). Written informed consent was obtained from participants. A prospective
observational cohort study was undertaken to assess peripheral axonal excitability in patients with
chronic migraine before, during and after treatment with a subcutaneous lignocaine and ketamine
infusion administered as part of a management plan as determined by the patient’s treating
neurologist. Inclusion and exclusion criteria are detailed in Table 2.
Table 2: Inclusion and Exclusion Criteria
Inclusion Criteria

Exclusion Criteria

Age 18-70

Pregnancy
1

Diagnosis of chronic migraine per IHS criteria

Breast feeding

refractory to first line therapies
Pre-treatment headache diary indicates diagnosis of

Women of child bearing potential not willing to avoid

transformed migraine in the 90 days prior to

pregnancy during the study timeframe

treatment.

1

Headache refractory to conventional management

Prolonged QT or history of malignant arrhythmia

Clinician decision to prescribe infusion

Allergy to lignocaine or ketamine

IHS = International Headache Society
Review of clinical state, headache diary and medications was undertaken in each assessment at

four-time points: baseline (Day 0; immediately before infusion), day 5 of infusion, and at 3 and six
months after infusion. Nerve excitability studies were also performed at these time points. The
study was not designed to alter or direct treatment but to observe their course over time.
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Infusion protocol
The infusion protocol is described in detail elsewhere (Rofe et al., 2019). To summarise, a
preparation containing 1g lignocaine and 250mg ketamine was diluted in 0.9% normal saline to a
total volume of 24 ml. Continuous subcutaneous infusion was delivered via a syringe driver
through a 22 gauge butterfly cannula to the subcutaneous tissue of the lateral abdominal wall or
outer thigh and secured by a large transparent adhesive dressing. The infusion was titrated over 24
-48 hours and continued until adequate analgesia was reached or non-efficacy was established for
a mean duration of11 days (range 6 - 22 days )The target rate of infusion was 1.0 ml/hour with
range of 0.5ml/hour to 1.5ml/hour depending on clinical response.
Nerve excitability studies: the TROND protocol
As with nerve conduction studies, nerve excitability studies involve stimulation of a peripheral
nerve and recording of a compound muscle action potential (CMAP) or sensory nerve action
potential (SNAP) in large myelinated fibres. Whereas nerve conduction studies use supramaximal
stimuli to capture latency, velocity and maximal amplitude of the nerve, excitability studies use
much weaker stimuli that excite a fixed fraction of axons to obtain a target response. Throughout
the study, conditioning stimuli are applied to the nerve and these depolarising or hyperpolarising
conditioning stimuli serve to change membrane potential. As a result, the test stimulus current
required to activate the target response will be affected by polarisation and reflects the active and
passive properties of the axonal membrane. . It is this change in stimulus that is then measured
(Bostock et al., 1998; Kiernan et al., 2000a; Burke et al., 2001) and from this measurement of
change, excitability properties of the internodal membrane can be indirectly evaluated (Nodera and
Kaji, 2006).
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In this study, the semi-automated TROND protocol of axonal excitability studies, based on the
principle of ‘threshold tracking’, was used for the assessment (Kiernan et al, 2000). A single
study took 10-15 minutes to complete. At the start of each study, a target response was established
using a stimulus-response curve the median nerve was stimulated at the wrist and the motor
response recorded over the abductor pollicis brevis using non-polarizable Ag/AgCl electrodes (See
Fig. 1). The QTRAC software (© Prof Hugh Bostock, UCL) delivered stimuli by a DS5 linear
bipolar stimulator (Digitmer, UK), via a data acquisition system. The HumBug (Quest Scientific,
Canada) eliminated 50 Hz interference.
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Figure 1 Nerve Excitability Set up

Legend to Figure 1
i.
A.
B.
C.
D.
E.

Nerve excitability Equipment
Personal computer
Data acquisition system
Digitimer DS5 linear bipolar stimulator
D440 isolated preamplifier
Humbug for 50-Hz interference elimination

ii.
Electrode position for median nerve motor study
A. Anode placed approx 10 cm proximal to wrist, positioned away from course of median
nerve
B. Stimulating cathode at the wrist over median nerve, approximately 1cm proximal to palmar
crease
C. Recording electrode over abductor pollicis brevis over the muscle belly
D. Reference electrode
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The target response was 40% of the maximal response on the stimulus-response curve (identified
at the steepest part of and therefore sensitive to change in threshold). The stimulus required to
produce the target response is known as the ‘threshold’ and it is this threshold response that is
tracked throughout the rest of the study. The TROND protocol obtains the following four
measurements.
1. Strength–duration properties: determined by measuring the thresholds for unconditioned
test stimuli of 0.2 - 1.0 ms duration. From this measurement, rheobase and the strengthduration time constant are derived using Weiss's law (Weiss, 1901; Bostock, 1983;
Mogyoros et al., 1996). These properties are influenced by nodal persistent Na+ currents
which are active at resting membrane potential (Bostock and Rothwell., 1997).
2. Current–threshold relationship: the threshold for producing the test response is measured at
the end of 200-ms conditioning currents which have strengths of between +50%
(depolarising) and –100% (hyperpolarising) of the threshold stimulus. The change in
threshold measured this way reflects the rectifying properties of the axon at both the nodal
and internodal axolemmas. Specifically it measures outward rectification due to fast and
slow K+ channels activity induced by depolarising currents and hyperpolarisation-activated
inwardly rectifying currents (IH) activated by hyperpolarising currents.
3. Threshold electrotonus: measures the change in threshold in response to subthreshold
depolarising and hyperpolarising conditioning stimuli of fixed strength (Bostock and
Baker, 1988). A standard threshold electrotonus study measures the change in threshold
before, during and after subthreshold conditioning stimuli of 100-ms duration which alter
the potential difference across the axonal membrane. Threshold electrotonus provides
insight into internodal conductances in vivo (Bostock et al., 1998; Burke et al., 2001)
62

including fast and slow K+ channel activity, Na+ channel activity and IH. Subthreshold
depolarising conditioning stimuli are applied at a fraction of the control threshold (+20% or
+40%), increasing nerve excitability and thereby decreasing threshold. Hyperpolarising
conditioning stimuli at strengths of -20%, -40%, of the target threshold serve to increase
threshold and decrease the excitability of the nerve.
4. Recovery cycle: measured using a supramaximal conditioning stimulus followed by a test
stimulus at varying conditioning-test intervals from 2 to 200 ms (Bostock et al., 1998;
Kiernan et al., 2000). The relative refractory period and the subsequent measurements of
superexcitability and late subexcitability during recovery following an action potential
reflect internodal resistance pathways through and under the myelin sheath and internodal
capacitance (Barrett & Barrett, 1982; Burke et al, 2001) Measurements are sensitive to
juxta-paranodal fast K+ channels and internodal slow K+ channels.

Statistical analysis
Statistical analysis was performed using the QTRAC-P programme with statistical significance set
at P value of less than 0.05. Data from 30 age-matched control subjects (Tomlinson et al., 2013)
was used to perform a repeated-measures analysis of variance (ANOVA) between control data and
mean data from each of three time points: baseline, Day 5 of infusion and at six months follow up.
Unpaired T-tests were also performed comparing control data to each of these data. Plots of
excitability measurements were generated using the QTRAC-P programme.
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Results
Patient demographics and outcomes
Clinical outcome of the response to the subcutaneous lignocaine and ketamine infusion is reported
elsewhere (Rofe et al., 2019). Fourteen patients were recruited (9 female) with a mean age of 43
years. At six months, 13 patients had sustained benefit from admission, characterised by
conversion to episodic migraine rather than chronic migraine in 6/14 patients using ICHD criteria.
One patient remained headache-free at the six month follow up. Improvement in chronic migraine
was reported by 6.
Change in medications
Individualised care of all patients during the time frame included review of preventative and
abortive medications. Medications at baseline and at six months are detailed in Appendix 1. A
combination of antidepressant and anticonvulsant medications were used for headache control in
10 patients at six months. All patients had tried several first line and second line preventative
medications in the past, with continuance precluded by inefficacy or intolerability. Reflecting this,
second line preventative agents were often prescribed and the most frequently prescribed
medications at six month follow up in addition to botulinum toxin (6) included lamotrigine (6) and
the selective serotonin reuptake inhibitors (SSRI) or serotonin noradrenaline reuptake inhibitors
(SNRI) antidepressants (6). Other commonly prescribed preventative agents at six months
included gabapentin (4), topiramate (4) and tricyclic antidepressants (3/14). The importance of
sleep restoration was reflected in prescription of quetiapine (2/14), agomelatine (2/14) and
melatonin (1/14).
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Nerve excitability studies
All 14 patients underwent nerve excitability studies at baseline (prior to infusion). Twelve patients
completed excitability studies on Day 5 of infusion. Two were experiencing recalcitrant analgesic
withdrawal headache on Day 5 and were disinclined to undergo studies at that time point. The
study was not designed to alter patients’ clinical course and, in this context, excitability studies
were only performed on the 5 patients that attended at follow up at three months. Nine patients
attended follow up at the six month mark and underwent studies at this time. Clinical data
(including list of medications) were collected over the telephone or from chart review in those
patients not attending at the three and six month time points. Statistical analysis was performed
using the QTRAC-P programme with statistical significance set at P value of less than 0.05.
ANOVA was used to compare differences in measurements of strength-duration, current
threshold-relationship, threshold electrotonus and the recovery cycle between mean control data
and mean data from each of three time points: baseline, Day 5 of infusion and at six months follow
up (Appendix 2). Temperature, age and sex were also recorded. Data plotted from the 3 time
points compared to normal controls are depicted in Figure 2. Unpaired T-tests were also
performed comparing control data to each of these data (Appendix 2).
Controls were age matched (mean age controls 39.1 years; mean age patients 42.9 years). There
was a greater proportion of women in the patient cohort (65% in patient cohort vs 50% in control
group), and mean temperature was lower in the serial patient recordings (33.25 °C in control group
vs 32.23°C -32.45 °C in patient groups). There was no statistically significant difference in
measurements of membrane excitability attributable to chronic migraine, the impact of the
lignocaine infusion, medications used to treat migraine or change in clinical state when compared
to normal control data. ANOVA identified changes only in peak response and stimulus required to
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produce a half-maximal response which were attributed to operator technique rather than based in
physiologic differences. Occasional minor changes in single measurements seen were noted seen
attributable to either operator technique (which produced variability in stimulus required for 50%
CMAP and peak CMAP response) or temperature (which produced changes in rheobase and
Ted10-20 in the baseline study; in Ted 40-60, accommodation half time and superexcitability at
7ms in the six month follow up study).
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Figure 2: Nerve excitability Studies in Patients with Chronic Migraine

Legend to Figure 2
Black line = control (n=30); Green = patient baseline (n=14) Red = patient six months (n=9),
Blue; Mean +/- standard error bars shown.
67

Discussion
This observational cohort study aimed to determine if nerve excitability studies could detect in
vivo difference in chronic migraneurs compared to healthy volunteers and therefore provide a
useful potential biomarker of disease. It was hypothesised that the excitability studies may detect
the in vivo effect of the lignocaine and ketamine infusion and that a change in clinical state at six
months may be reflected in change in peripheral axonal excitability. At baseline and throughout
the study, all patients were taking medications that potentially impact axonal excitability via
exerting effect on ion channel function or neurotransmitter activity. However, with consideration
of clinical equipoise in this situation and the observational structure of the study, withdrawal of
medication to study the patients at baseline off-treatment was felt beyond the scope of this project.
There are no published data regarding the impact of oral anticonvulsant or antidepressant
medications on peripheral axonal excitability studies.
The cohort of chronic migraine patients described here reflect the more severe end of the spectrum
seen in by headache specialists, manifesting disabling symptoms and significant disruption of the
normalcy of life. While not first line treatment, both lignocaine and ketamine have been described
to be beneficial in migraine management and may have a role in curtailing chronic headache
(Williams DJ and Stark RJ, 2003; Lauritsen et al.,2016). This study has not detected a change in
peripheral nerve excitability in a chronic migraine population before, during and after treatment
with a subcutaneous lignocaine and ketamine infusion despite clinical response in all but one
patient. However, the present findings generate considerations of (i) applicability of nerve
excitability studies in migraneurs, (ii) applicability of excitability studies in patients on
medications which modify axonal excitability, (iii) mechanism of action of the lignocaine and
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ketamine infusion and (iv) the bioavailability of lignocaine and ketamine at the level of the
peripheral axon.
Nerve excitability studies in chronic migraine patients
The patients with heterogenous chronic migraine show no difference in excitability at baseline
compared to healthy volunteers. Studies were performed while patients were taking
neuromodulatory agents, and had been doing so for some time. It might be considered that the
doses of the medications used (such as lamotrigine, sodium valproate, gabapentin and
amitriptyline) were often used at lower doses than are prescribed for their other indications for
their use (such as seizure disorders or depression), and that these medications might produce an
effect on peripheral axonal excitability if given in larger doses. However, alterations in nerve
conduction studies have been demonstrated with topiramate or sodium valproate (Freeman et al.,
2007; Boylu et al., 2010) although Erdogan et al, 2012 did identify changes in nerve excitabilities
studies attributable to topiramate. Alternatively, it might be considered that the chronic migraine
patients could have a variation of peripheral axonal excitability at baseline if recorded off
medication and the impact of the neuromodulatory agents prescribed for headache control serves
to normalised those variations. The most likely explanation is that the peripheral axon is not a
reliable biomarker of chronic migraine, in which the dominant mechanism of headache may be
related to entrenchment of central pathways and is unlikely to affect peripheral nerve axonal
excitability.
Applicability of excitability studies in patients on medications which modify axonal excitability
When considering the reports of the high sensitivity with which excitability studies identify
detectable sodium channel blockade in nerves affected by lignocaine local injection (Moldovan et
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al., 2014), the likely explanation for the normal studies in the patient cohort during the lignocaine
infusion is that the doses used are too small when systemically distributed by subcutaneous
infusion to exert impact in vivo in the peripheral nerve axon, rather than the lignocaine not
modifying peripheral nerve excitability. The same could be postulated for the oral medications
used by the patients. The lack of change in this cohort has important implications for using nerve
excitability studies in the evaluation of patients with neurological disorders or medication effects,
particularly where the disease mechanism or drug effect is postulated to act via dysfunction of
membrane excitability (for example epilepsy, pain, neuromuscular disease). With reference to
clinical equipoise, it may not be possible to withdraw neuromodulatory medications in these
cohorts (especially, for example, in patients with epilepsy).

However, this study finds that the

oral medications prescribed (Appendix 1) do not impact nerve excitability study recordings in
vivo. Therefore if a significant change in axonal excitability studies is identified in the study of a
relevant disorder or medication, it might be better attributed to the disease process/study drug
mechanism with the knowledge that the oral medications used in these patients do not translate to
a significant effect.
Inference regarding mechanism of action of the lignocaine and ketamine infusion
All patients had clinical benefit from the lignocaine and ketamine infusion during the treatment in
hospital with reduction of headache. However, no change was demonstrated in axonal excitability
studies. While it may not be expected that ketamine produce a change in axonal excitability,
demonstrable effect on nerve excitability studies with lignocaine has been documented (Moldovan
et al., 2014). It could therefore be extrapolated that the prolonged infusion acts via a central
mechanisms in stabilising the aberrant hyperexcitability in the entrenched central pathways that
perpetuate chronic migraine and give patients a reduced threshold to trigger migraine.
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Future directions
While this study has not demonstrated a biomarker in a heterogeneous population of chronic
migraneurs on treatment, helpful observations regarding use of the nerve excitability studies in
medicated patients has been documented which may be useful in future studies in migraine or
other conditions. There may be a role for using axonal excitability studies in other headache
cohorts in which peripheral nerve activity may be more relevant and where a more closely related
nerve could be studied (e.g. trigeminal autonomic cephalgias, migraine due to genetic
channelopathy). Further, there is potentially a role for use of excitability studies to be used to
measure the in vivo impact of therapeutic agents if the mechanism of action is exerted by
modulation of axonal excitability or membrane potential.
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CHAPTER

4

Conclusion

The studies in this thesis have investigated in a prospective observational study whether patients
suffering from severe chronic migraine and healthy age matched patients could be differentiated in
terms of nerve membrane potentials via nerve excitability studies and longitudinally with therapeutic
response.
A pilot study of clinical response to low dose lignocaine and ketamine subcutaneous infusion in
refractory chronic migraine populations provided data that supports the use of this protocol to reduce
long term migraine medication requirements. The pilot study established a high level of clinical
safety and patient satisfaction with clinical outcomes although the study did not confirm that the
infusions of lignocaine and ketamine were sole effective management in achieving the patient
outcomes.
This outcome suggests that central desentisation may be achieved along with removal of medication
overuse headache contributions to chronic migraine.
We hypothesised that peripheral nerve excitability studies that measure changes in the membrane
potential of nerves may be potentially useful as biomarkers for migraine physiology and predict
treatment response.

We tested this hypothesis in a population of CM and compared nerve

excitability responses to an age matched normal control population.
The nerve excitability studies did not identify significant alterations in peripheral ion channels
following therapeutic intervention with low-dose lignocaine/ketamine infusion. Effective
biomarkers in chronic migraine were not identified. Standard pain management modalities generally
considered to act via sodium and calcium channel modification had no significant effect on
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excitability parameters. However, significant clinical improvement did result from therapeutic
interventions; the mechanism(s) for this improvement are uncertain but are likely to be independent
of changes in nerve membrane potentials.
This study provides the first published data on NES in a chronic migraine cohort on medication.
Thus, despite the results showing no significant differences to controls, it has important implications
for other CNS diseases where differences have been found in participants, who are on medications
that act via similar mechanisms.
Future studies investigating central sensitisation role in the maintenance of chronic migraine will
allow new novel treatments to benefit this refractory population. There may be a role for using
axonal excitability studies in other headache cohorts in which peripheral nerve activity may be more
relevant and where a more closely related nerve could be studied (e.g. trigeminal autonomic
cephalgias, migraine due to genetic channelopathy). Further, there is a potential role for excitability
studies to measure the in-vivo impact of therapeutic agents if the mechanism of action is exerted by
modulation of axonal excitability or membrane potential.

Key Points:


This study confirms that a low does subcutaneous lignocaine and ketamine infusion is a
safe management technique for patients with a severe refractory migraine and chronic
migraine.



The study fills a current gap in the literature and strengthens clinical evidence from other
published data on NES’s application as an investigatory tool in channelopathy disease
states where unique patterns have been found.



Presumed central desensitisation and removal of medication overuse factors in the chronic
migraine can be achieved.



Study shows the chronic migraine population on medication have similar nerve excitability
profile to normal control population.



In the presence of a clinical response, the lack of detectable change in peripheral nerve ion
channel function suggest that lignocaine/ketamine infusion acts via central mechanisms in
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stabilising the aberrant hyperexcitability in the entrenched central pathways that perpetuate
chronic migraine and give patients a reduced threshold to trigger migraine.


Study shows stability of nerve excitability in patients whose drug doses and drug types
have been modified within standard therapeutic ranges.



Nerve excitability studies are not suitable to be used as a biomarker for treatment responses
at therapeutic doses.



There may be a role for using axonal excitability studies in other headache cohorts in
which peripheral nerve activity may be more relevant and where a more closely related
nerve could be studied (e.g. trigeminal autonomic cephalgias, migraine due to genetic
channelopathy).



There is a potential role for excitability studies to measure the in-vivo impact of therapeutic
agents if the mechanism of action is exerted by modulation of axonal excitability or
membrane potential.
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3. Patient information and consent form - Clean

Participant Information Sheet/Consent Form
Interventional Study - Adult providing own consent

[Insert site name]
Study Title: Prospective observational study examining the effectiveness of
subcutaneous lignocaine and ketamine infusion
in management of transformed migraine.
Short Title:

Management of transformed migraine

Protocol number:

1

Principal Investigator:

A/Prof Susan Tomlinson

Associate Investigator(s)

[Invesitgator(s)]

Location:

[Location]

Part 1: What does my participation involve?
You are being invited to take part in this research because you have a history of migraine.
The study is designed to observe the effectiveness of your management. Participation in the
study will not influence or direct the type of management you receive. Sometimes migraine
management involves an admission to hospital for a subcutaneous infusion of medication that
controls pain (lignocaine and ketamine). The research project aims to observe whether use
of this infusion makes a difference in frequency or severity of migraine. If the appropriate
individualized care of migraine involves admission for the infusion, your response will be
measured. If you do not receive the infusion, your response will also be measured as a ‘nonintervention ’subject (i.e. not receiving the treatment of interest).
This Participant Information Sheet/Consent Form tells you about the research project. It
explains the tests and treatments involved. Knowing what is involved will help you decide if
you want to take part in the research. Please read this information carefully. Ask questions
about anything that you don’t understand or want to know more about. Before deciding
whether or not to take part, you might want to talk about it with a relative, friend or your local
doctor.
Participation in this research is voluntary. If you don’t wish to take part, you don’t have to. You
will receive the best possible care whether or not you take part.
If you decide you want to take part in the research project, you will be asked to sign the
consent section. By signing it you are telling us that you:
• Understand what you have read
• Consent to take part in the research project
• Consent to have the tests and treatments that are described
• Consent to the use of your personal and health information as described.
You will be given a copy of this Participant Information and Consent Form to keep.
1. Introduction
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Migraine is a common condition in women and can significantly affect a person's quality of
life, relationships and financial situation. Over seven percent of patients can develop daily or
near-daily migraine, described as chronic or transformed migraine. While not life-threatening,
transformed migraine can be debilitating and the best treatment options are not clearly
defined.
2. What is the purpose of this research?
Use of intravenous lignocaine has been shown to be effective in treatment of acute migraine.
Ketamine is widely used for treatment of neuropathic headache. A protocol for the use of
subcutaneous lignocaine and ketamine infusion for treatment of chronic pain including
transformed migraine has been in place for many years at St Vincent’s Private Hospital.
Studies have shown that the medications can be given safely and effectively in low dose and
can that a prolonged infusion (7 to 10 days) is more effective than a short infusion (ie single
does) to abort the headache cycle. The protocol used at St Vincent’s Private Hospital is
based on treatments used in analogous pain units internationally. Anecdotally, the infusion
renders great benefit for patients with transformed migraine. However, there are no published
data to document this treatment as effective. Therefore, we aim to follow patients with
transformed migraine to determine if the patients receiving the infusion have a better
outcome.
This research has been initiated by the study doctor, A/Prof Susan Tomlinson (Neurologist,
St. Vincent’s Clinic), in collaboration with A/Prof Ray Garrick (St. Vincent’s Clinic and Prof
Bruce Brew).

3. What does participation in this research involve?
This study is aimed to observe the result of your migraine management. Your management
will be tailored to your individual needs based on best practice and not determined by the
study. If you decide to participate in this study, we ask that you complete 9-month (270 day)
period of headache monitoring under the Neurologist at [Insert site name].
During this time, as part of the management for migraine, your neurologist may discuss the
appropriateness of an admission to St Vincent’s Private Hospital for treatment with the
subcutaneous lignocaine and ketamine infusion. Unfortunately this treatment is not currently
available through the public health service. Therefore, only patients with adequate private
health cover will be able to receive the infusion, which is currently the case in standard clinical
care. Once the infusion has taken place, you will be asked to complete a further 180-day (6
month) headache diary so we can evaluate the outcome of your treatment.
If no infusion is advisable, you will be eligible to participate in the study as a non-intervention
participant and will complete the 9 month surveillance period while using your standard
migraine treatment.
As per standard practice, you will also require a follow-up appointment with your Neurologist
approximately 3 months and 6 months after your infusion or after you commence participation
in the non-intervention group. There is no additional cost to you for participation, other than
that which would normally be incurred as part of standard management.
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4. What do I have to do?
Your involvement will involve four short research visits. The information collected at each visit
will include your medical history and investigation results, clinical examination findings and
medication use. A short questionnaire will be used to standardize measurement of treatment
response. Between visits, you will keep a simple headache diary which is frequently used in
the clinical setting.
In addition to the clinical assessment and questionnaire, each study visit will involve a brief
electrical test of the nerves in your forearm. This test is called a nerve excitability study and
involves stimulating the median nerve in the wrist with short electrical pulses. The electrical
pulses last milliseconds only. They may be mildly uncomfortable but there are not long term
side effects. The test can be stopped at any time, should you require. Nerve excitability
studies are a research tool that assesses how the infusion settles the nerve during treatment.
The nerve excitability studies will be performed on 4 occasions during 9 months: at baseline,
during the admission for infusion (Day 5) or at 90 days after initial assessment, then repeated
at 3 and six months after the infusion or at 3 and six months after the second assessment.
5. Other relevant information
It is anticipated that approximately 40 people will complete this study. Information about your
response to your treatment will be analysed. Two groups will be observed including are those
whose standard care involves no infusion for their migraine, are those who receive the
infusion. All participants will be seen by their Neurologist at [Insert site name].over a
minimum of four appointments.
6. Do I have to take part in this project?
Participation in any research project is voluntary. If you do not wish to take part, you do not
have to. If you decide to take part and later change your mind, you are free to withdraw from
the project at any stage. If you do decide to take part, you will be given this Participant
Information and Consent Form to sign and you will be given a copy to keep. Your decision
whether to take part or not to take part, or to take part and then withdraw, will not affect your
routine treatment, your relationship with those treating you or your relationship with [Insert

site name].
7. What are the alternatives to participation
You will be offered the standard of care for your migraine treatment, including other migrainepreventing drugs, regardless of whether you participate in the study. Your study doctor will
discuss these options of best practice with you before you decide whether or not to take part
in this research project.
8. What are the possible benefits of taking part?
We cannot guarantee or promise that you will receive any direct benefits from this research.
9. What are the possible risks of taking part?
There are no risks associated with this study because the study is designed to observe your
journey, not to prescribe specific treatments. Any risk of migraine management relates to the
individual therapies, which will only be prescribed after full discussion with you of the relevant
risks, benefits and alternatives, in keeping with best practice and standard clinical care. You
will be provided will information regarding all the appropriate treatment modalities.
10. What if new information arises during this research project?
Sometimes during the course of a research project, new information becomes available about
the treatment that is being studied. If this happens, your study doctor will tell you about it and
discuss with you whether you want to continue in the research project. If you decide to
withdraw, your study doctor will make arrangements for your regular health care to continue.
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withdraw, your study doctor will make arrangements for your regular health care to continue.
If you decide to continue in the research project you will be asked to sign an updated consent
form. On receiving new information, your study doctor might consider it to be in your best
interests to withdraw you from the research project. If this happens, he/ she will explain the
reasons and arrange for your regular health care to continue.
11. Can I have other treatments during this research project?
This is an observational study only. Any limitations on other treatments will be directed by
your neurologist, and according to the treatments chosen as best appropriate for you.
Participation in this study will not prevent you from using medications that may help your
migraine management when indicated. It is important to tell your study doctor and the study
staff about any treatments or medications you may be taking, including over-the-counter
medications, vitamins or herbal remedies, acupuncture or other alternative treatments. You
should also tell your study doctor about any changes to these during your participation in the
research project.
12. What if I withdraw from this research project?
If you decide to withdraw from the project, please notify a member of the research team. This
notice will allow that person or the research supervisor to discuss any health risks or special
requirements linked to withdrawing.
If you do withdraw your consent during the research project, the study doctor and relevant
study staff will not collect additional personal information from you, although personal
information already collected will be retained to ensure that the results of the research project
can be measured properly and to comply with law. You should be aware that data collected
by the investigators up to the time you withdraw will form part of the research project results.
If you do not want them to do this, you must tell them before you join the research project.
13. Could this research project be stopped unexpectedly?
It is unlikely that this would happen. However, this will not impact your medical care. You will
be informed if the study is stopped.
14. What happens when this research project ends?
You will continue to receive the appropriate management by your treating doctors as clinically
indicated.

Part 2 How is this research project being conducted?
15. What will happen to information about me?
By signing the consent form you consent to the study doctor and relevant research staff
collecting and using personal information about you for the research project. Any information
obtained in connection with this research project that can identify you will remain confidential
and be stored securely. Your information will only be used for the purpose of this research
project and it will only be disclosed with your permission, except as required by law.
Information about you may be obtained from your health records held at this and other health
services for the purpose of this research. By signing the consent form you agree to the study
team accessing health records if they are relevant to your participation in this research
project.
It is anticipated that the results of this research project will be published and/or presented in a
variety of forums. In any publication and/or presentation, information will be provided in such
a way that you cannot be identified, except with your permission. All information about
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participants in the study will be presented as group means and descriptive statistics, such that
it will be impossible to identify a particular participant in any way.
Information about your participation in this research project may be recorded in your health
records.
In accordance with relevant Australian and NSW privacy and other relevant laws, you have
the right to request access to your information collected and stored by the research team. You
also have the right to request that any information with which you disagree be corrected.
Please contact the study team member named at the end of this document if you would like to
access your information.
Any information obtained for the purpose of this research project that can identify you will be
treated as confidential and securely stored. It will be disclosed only with your permission, or
as required by law.

16

Complaints and compensation

If you suffer any injuries or complications as a result of this research project, you should
contact the study team as soon as possible and you will be assisted with arranging
appropriate medical treatment. If you are eligible for Medicare, you can receive any medical
treatment required to treat the injury or complication, free of charge, as a public patient in any
Australian public hospital.
18

Who is organising and funding the research?

This research project is being conducted by A/Prof Susan Tomlinson (Neurologist, St.
Vincent’s Clinic). No member of the research team will receive a personal financial benefit
from your involvement in this research project (other than their ordinary wages). The
Neurologists involved in the study and St. Vincent’s Clinic/Hospital have no conflicts of
interest with regard to this research. The study is supported by a grant from the St Vincent’s
Clinic Research Foundation.
19

Who has reviewed the research project?

All research in Australia involving humans is reviewed by an independent group of people
called a Human Research Ethics Committee (HREC). The ethical aspects of this research
project have been approved by the HREC of St Vincent’s Hospital, Sydney.
This project will be carried out according to the National Statement on Ethical Conduct in
Human Research (2007). This statement has been developed to protect the interests of
people who agree to participate in human research studies.
The study was peer reviewed as part of the process of application for the St Vincent’s Clinic
Foundation Grant Application Process.
20

Further information and who to contact

The person you may need to contact will depend on the nature of your query. If you want
any further information concerning this project or if you have any medical problems which
may be related to your involvement in the project (for example, any side effects), you can
contact the principal study doctor, A/Prof Susan Tomlinson on 8382 6712 or any of the
following people:
Clinical contact person
Name
Position
Telephone
Email

A/Prof Susan Tomlinson
Neurologist
83826712
sydheadache@svha.com.au
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For matters relating to research at the site at which you are participating, the details of the
local site complaints person are:
Complaints contact person
Position
Research Office Manager
Telephone
02 8382 2075
Email
SVHS.Research@svha.org.au
If you have any complaints about any aspect of the project, the way it is being conducted or
any questions about being a research participant in general, then you may contact:
Reviewing HREC approving this research and HREC Executive Officer details
Reviewing HREC name
HREC Executive Officer
Telephone
Email

St Vincent’s Hospital HREC
Executive Officer
02 8382 2075
SVHS.Research@svha.org.au
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Consent Form - Adult providing own consent
Title

Prospective observational study examining the
effectiveness of subcutaneous lignocaine and ketamine
infusion

Short Title

Management of Transformed Migraine

Protocol Number

1

Project Sponsor

None

Coordinating Principal
Investigator/ Principal Investigator

A/Prof Susan Tomlinson

Associate Investigator(s)

Location

[Investigator(s)]
[Location]

Declaration by Participant
I have read the Participant Information Sheet or someone has read it to me in a language that
I understand.
I understand the purposes, procedures and risks of the research described in the project.
I give permission for my doctors, other health professionals, hospitals or laboratories outside
this hospital to release information to St Vincent’s Clinic, concerning my disease and
treatment for the purposes of this project. I understand that such information will remain
confidential.
I have had an opportunity to ask questions and I am satisfied with the answers I have
received.
I freely agree to participate in this research project as described and understand that I am free
to withdraw at any time during the study without affecting my future health care.
I understand that I will be given a signed copy of this document to keep.
Name of Participant (please print)
Signature

Date

Declaration by Study Doctor/Senior Researcher†
I have given a verbal explanation of the research project, its procedures and risks and I
believe that the participant has understood that explanation.
Name of Study Doctor/
Senior Researcher† (please print)
Signature

Date

†

A senior member of the research team must provide the explanation of, and information concerning,
the research project.

Note: All parties signing the consent section must date their own signature.
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Form for Withdrawal of Participation - Adult providing own
consent

Title
Short Title

Prospective observational study examining
the effectiveness of subcutaneous lignocaine
and ketamine infusion
in management of transformed migraine.
Management of Transformed Migraine

Protocol Number

1

Project Sponsor

None

Coordinating Principal Investigator/ Principal
Investigator

A/Prof Susan Tomlinson

Associate Investigator(s)

Location

[Investigator(s)]

[Location]

Declaration by Participant
I wish to withdraw from participation in the above research project and understand that such
withdrawal will not affect my routine treatment, my relationship with those treating me or my
relationship with St. Vincent’s Clinic, St. Vincent’s Hospital or my treating doctor.

Name of Participant (please print)
Signature

Date

Circumstances for withdrawal (if given verbally)

Declaration by Study Doctor/Senior Researcher†
I have given a verbal explanation of the implications of withdrawal from the research project
and I believe that the participant has understood that explanation.

Name of Study Doctor/
Senior Researcher† (please print)
Signature

Date

†

A senior member of the research team must provide the explanation of and information concerning
withdrawal from the research project.

Note: All parties signing the consent section must date their own signature.
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4. Migraine Disability and Assessment Score (MIDAS)
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5. Headache Diary
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6. Nerve excitability studies configuration

Figure 6.1: Nerve Excitability equipment
Hardware:
16-bit data acquisition Analogue to digital system (National Scientific)
DS5 linear constant-current bipolar stimulator (Digitimer)
D440-2 amplifier (Digitimer)
Humbug 50/60 Hz eliminator (Quest scientific)
Laptop with QtracS stimulation software (© Professor H Bostock, University College London)
Peripheral cables and disposable electrodes
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Tests were performed on the participant’s median nerve with six surface electrodes (per Figure 6.2 set up).
Compound action potentials were recorded along the abductor pollicis brevis after stimulation of the
median nerve near the wrist. Current was delivered from DS5 stimulators and controlled through the
QtracS stimulation software following the TRONDNF protocol. Recording of compound action potentials
were measured through the D440 amplifier and then routed through a humbug to remove background noise.

Figure 6.2: Electrode placement
(Note: Two electrodes are also located on the back of the hand and on the forearm and are attached
with earth cables)
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7. Medical History Worksheet
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8. Medication summary of participants
Appendix 8 lists the headache medication that the participant was taking at each respective timepoint.

Table Summary of Medication changes
Patient 1
Baseline
PREVENTIVE AGENTS Amytriptyline 50 mg
Sodium valproate 200mg bd

6 months
Amytriptyline 50mg
Meloxicam 15mg
Verapamil 40mg bd
Gabapentin 600 bd
Botulinum toxin

ABORTIVE AGENTS

Ibuprofen
Codeine phosphate

Patient 2
PREVENTIVE AGENTS

Baseline
Amytriptyline 50
Topiramate 50
Codeine phosphate

6 months
Sodium valproate 200mg bd

ABORTIVE AGENTS
Patient 3
PREVENTIVE AGENTS

-Baseline
Gabapentin 200mg mane, 300mg
nocte
Lamotrigine 100mg bd
Duloxetine 120mg
Baclofen 5mg mane
Botulinum toxin

-6 months
Gabapentin 200mg bd
Lamotrigine 50mg bd
Duloxetine 120mg
Botulinum toxin
Topiramate 50mg bd

ABORTIVE AGENTS

Paracetemol
Celecoxib
Rizatriptan
Diazepam

Paracetamol
Celecoxib
Rizatriptan
Diazepam
Sub occcipital blocks

Patient 4
PREVENTIVE AGENTS

Baseline
Zonisamide
Botulinum toxin
Lamotrigine 200mg daily
Duloxetine 120mg

6 months
Propranolol 10mg bd
Botulinum toxin
Lamotrigine 400mg daily
Duloxetine 180mg

ABORTIVE AGENTS

--

Meloxicam 15mg daily
Sub occciptial blocks

Patient 5

Baseline

6 months
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PREVENTIVE AGENTS

Duloxetine 90mg
Agomelatine 25 mg
Botulinum toxin

Venlafaxine 75mg mane
Lamotrigine 75mg mane, 100mg nocte
Quetiapine 25mg nocte
Botulinum toxin

ABORTIVE AGENTS

Naproxyn 250mg

Naproxyn 250mg

Patient 6
PREVENTIVE AGENTS

Baseline
Topiramate 50
Verapamil 40mg bd
Zolpidem

6 months
Zonisamide 25mg
Doxepin 25mg nocte

ABORTIVE AGENTS
Patient 7
PREVENTIVE AGENTS

-Baseline
Stopped diazepam and codeine prior
to admission

Subocciptal blocks
6 months
Agomelatine 50mg nocte
Duloxetine 120mg daily
Topiramate 100mg nocte

ABORTIVE AGENTS
Patient 8
PREVENTIVE AGENTS

-Baseline
--

Naproxen 200mg
6 months
Melatonin 2mg
Gabapentin 300mg daily

ABORTIVE AGENTS

--

Metaclopramide 10mg
Naproxen 200mg
Rizatriptan 10mg

Patient 9
PREVENTIVE AGENTS

Baseline
--

6 months
Magnesium 300mg bd
Quetiapine 25mg
Riboflavin 400mg
Zonisamide 50mg mane 100mg nocte
Amitriptyline 37.5mg nocte
Botulinum toxin

ABORTIVE AGENTS
Patient 10
PREVENTIVE AGENTS

Rizatriptan 3-4x/week
Baseline
Sodium valproate 1g mane, 500mg
nocte
Lamotrigine 100mg mane
Vitamin B2 400mg daily

ABORTIVE AGENTS

Maxalt 10mg prn
Ondansetron 4mg prn
Clonazepam 0.5mg prn

Patient 11

Baseline

6 months
Sodium valproate 1g mane, 500mg
nocte
Lamotrigine 100mg mane
Vitamin B2 400mg daily
Verapamil 40mg tds,

6 months
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PREVENTIVE AGENTS

Gabapentin 300mg tds Zonisamide
Sub occipital blocks

Gabapentin 400mg bd Amitriptyline
150
Wean Zonisamide
Sub occipital blocks

ABORTIVE AGENTS

--

--

Patient 12
PREVENTIVE AGENTS

Baseline
Topiramate 50mg mane and 100mg
nocte
Mexiletine 200mg bd
Oxytocin 60units bd
Magnesium
vitamin B2 400mg daily
Parecoxib IMI 40mg, Naratriptan
Codeine phosphate 30mg daily

6 months
Topiramate 50mg nocte
Lamotrigine 100mg bd
Botulinum toxin

Patient 13
PREVENTIVE AGENTS

Baseline
Lamotrigine 100mg bd
Agomelatine 50mg nocte
Amitriptyline 50mg nocte
Botulinum toxin

ABORTIVE AGENTS
Patient 14
PREVENTIVE AGENTS

-Baseline
Topiramate 50mg
Sertraline 50mg
--

6 months
Lamotrigine 100mg bd
Agomelatine 50mg nocte
Vortioxetine 15mg mane
Tapentadol SR 50mg prn
Naproxyn 250mg prn
Metaclopramide 10mg po
-6 months
Topiramate 25mg nocte
Gabapentin 200mg tds
--

ABORTIVE AGENTS

ABORTIVE AGENTS
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Parecoxib IMI 40mg, Occasional
codeine phosphate Naratriptan

9. Measurements used for analysis of Nerve Excitability Studies

Measurement

Definition

Strength-duration relationship (Figure 2B)
Strength-duration time
Estimated from the negative intercept on the X-axis of the plot of stimulus charge v.
constant: SDTC
stimulus duration (Fig. 2B )
Current/threshold relationship (Figure 2C and 2D)
Resting I/V slope
The slope of the current-threshold relationship in Fig2C. calculated from the polarising
currents -10% and +10% of threshold (see Fig. 2D)
Minimum I/V slope

Minimal slope of the curve in Fig. 2C

Hyperpolarising I/V slope

The leftmost point in Fig. 2D

Threshold electrotonus (Figure 2E)
Ted
Change in threshold in response to a subthreshold depolarising conditioning stimulus
TEd20

Threshold electrotonus in response to a subthreshold depolarising conditioning stimulus
which is 20% of threshold stimulus

TEd40

Threshold electrotonus in response to a subthreshold depolarising conditioning stimulus
which is 40% of threshold stimulus

TEd20(peak)

Peak % reduction in threshold during depolarising currents set to 20% of the resting
threshold ‡

TEd40(peak)

Peak % reduction in threshold during depolarising currents set to 40% of the resting
threshold ‡
Mean % threshold reductions between the specified latencies for the 40% depolarising
current

TEd40(90-100 ms)
TEd40(undershoot)

Minimal % threshold reduction after the 100 ms depolarising current ‡

TEd40(accom)

Maximal drop from TEd40(peak) during 100 ms depolarisation ‡

TEh

Change in threshold in response to a subthreshold hyperpolarising conditioning stimulus

40

TEh (90-100 ms)
TEh40(90-100 ms)
TEh40(overshoot)
Accommodation half time

As TEd40(90-100 ms) but hyperpolarising
As TEh40(90-100 ms) but during 20% hyperpolarising current
Maximal % threshold reduction after the 100 ms hyperpolarisation ‡
Half-time of accommodative response to a 100 ms subthreshold depolarising
conditioning stimulus

Recovery Cycle (Figure 2F)
Relative refractory period
Interstimulus interval at which threshold first returns to normal
(RRP)
Superexcitability

Maximal % threshold reduction †

Late Subexcitability

Maximal % threshold increase after 10 ms †

† = measurements averaged over 3 adjacent points; ‡ = measurements averaged over 20 ms
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i.

ANOVA comparing control data (n=30) with patient data at baseline (n=14); day 5 of the
lignocaine and ketamine infusion (n=12); and at six months follow up (n=9).

1. Stimulus (mA) for 50% m

F=4.425(3, 61)

p=0.00712**

3. Strength-duration\time

F=0.562(3, 61)

p=0.6461

4. Rheobase (mA)

F=2.717(3, 61)

p=0.05152

5. Stimulus-response\slope

F=0.641(3, 58)

p=0.59568

6. Peak response\(mv)

F=3.172(3, 59)

p=0.03033*

7. Resting I/V slope

F=0.407(3, 60)

p=0.75206

8. Minimum I/V slope

F=0.176(3, 60)

p=0.91001

9. Temperature ( C)

F=2.928(3, 59)

p=0.04039*

10. RRP (ms)

F=0.461(3, 60)

p=0.71454

11. TEh(90-100ms)

F=0.161(3, 61)

p=0.91909

12. TEd(10-20ms)

F=1.627(3, 61)

p=0.19103

13. Superexcitability (%)

F=1.238(3, 61)

p=0.30346

14. Subexcitability (%)

F=0.264(3, 61)

p=0.85147

17. Age (years)

F=1.132(3, 40)

p=0.34805

18. Sex (M=1, F=2)

F=0.738(3, 60)

p=0.53692

19. Latency (ms)

F=0.054(3, 61)

p=0.97766

20. TEd(40-60ms)

F=2.161(3, 61)

p=0.10043

21. TEd(90-100ms)

F=0.542(3, 61)

p=0.65952
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22. TEh(10-20ms)

F=1.022(3, 61)

p=0.39035

23. TEd(undershoot)

F=0.417(3, 61)

p=0.74473

24. TEh(overshoot)

F=1.416(3, 61)

p=0.24573

25. TEd(peak)

F=1.753(3, 61)

p=0.1641

26. S2 accommodation

F=1.09(3, 61)

p=0.36096

27. Accommodation half-tim

F=2.637(3, 61)

p=0.0567

28. Hyperpol. I/V slope

F=0.939(3, 60)

p=0.42912

29. Refractoriness at 2.5m

F=0.382(3, 60)

p=0.7691

30. TEh(20-40ms)

F=0.465(3, 61)

p=0.71175

31. TEh(slope 101-140ms)

F=0.28(3, 61)

p=0.84062

32. Refractoriness at 2 ms

F=0.261(3, 51)

p=0.8536

33. Superexcitability at 7

F=1.436(3, 60)

p=0.24021

34. Superexcitability at 5

F=0.895(3, 60)

p=0.45105

35. TEd20(peak)

F=0.575(3, 61)

p=0.63742

36. TEd40(Accom)

F=0.404(3, 42)

p=0.75387
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ii.

Unpaired t-test: comparing control data to baseline study in 14 patients with chronic
migraine.

Variable

Mean+/-SE(n)

Mean+/-SE(n)

t(df)

p

1. Stimulus (mA) for 50% m

4.287x|/1.04(30)

3.364x|/1.08(14

t=3.235(42)

p=0.00247**

3. Strength-duration\time

0.4807 ± 0.0184(30)

0.4439 ± 0.0151(14)

t=1.273(42)

p=0.2074

4. Rheobase (mA)

2.796x|/1.04(30)

2.266x|/1.09(14)

t=2.611(42)

p=0.01201*

5. Stimulus-response\slope

5.128x|/1.04(30)

5.371x|/1.07(14)

t=0.598(42)

p=0.56039

6. Peak response\(mv)

8.847x|/1.06(30)

7.249x|/1.12(14)

t=1.688(42)

p=0.09505

7. Resting I/V slope

0.6071 ± 0.0142(30)

0.6262 ± 0.0304(13)

t=0.652(41)

p=0.52533

8. Minimum I/V slope

0.2462 ± 0.008(30)

0.2448 ± 0.011(13)

t=0.103(41)

p=0.88212

9. Temperature ( C)

33.25 ± 0.17(30)

32.45 ± 0.283(12)

t=2.48(40)

p=0.01666*

10. RRP (ms)

2.953x|/1.02(30)

3.017x|/1.04(13)

t=0.519(41)

p=0.61237

11. TEh(90-100ms)

-116.7 ± 2.77(30)

-114.2 ± 4.83(14)

t=0.486(42)

p=0.63436

12. TEd(10-20ms)

68.69 ± 0.744(30)

65.91 ± 1.14(14)

t=2.079(42)

p=0.04148*

13. Superexcitability (%)

-23.05 ± 0.926(30)

-20.96 ± 2.47(14)

t=0.969(42)

p=0.34032

14. Subexcitability (%)

14.4 ± 0.655(30)

14.24 ± 1.47(14)

t=0.118(42)

p=0.87344

17. Age (years)

39.1 ± 2.4(30)

42.89 ± 4.23(9)

t=0.763(37)

p=0.45629

18. Sex (M=1, F=2)

1.467 ± 0.0926(30)

1.615 ± 0.14(13)

t=0.883(41)

p=0.38619

19. Latency (ms)

6.468 ± 0.114(30)

6.419 ± 0.257(14)

t=0.203(42)

p=0.82147

20. TEd(40-60ms)

50.66 ± 0.667(30)

49.99 ± 0.884(14)

t=0.58(42)

p=0.57188

21. TEd(90-100ms)

43.96 ± 0.663(30)

43.18 ± 0.962(14)

t=0.662(42)

p=0.51842

22. TEh(10-20ms)

-73.55 ± 0.732(30)

-72.72 ± 1.18(14)

t=0.621(42)

p=0.54542

23. TEd(undershoot)

-18.78 ± 0.604(30)

-17.8 ± 1.23(14)

t=0.808(42)

p=0.42909

24. TEh(overshoot)

14.06 ± 0.597(30)

12.16 ± 1.33(14)

t=1.511(42)

p=0.13431
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25. TEd(peak)

68.17 ± 0.696(30)

65.68 ± 1.08(14)

t=1.985(42)

p=0.05098

26. S2 accommodation

24.21 ± 0.528(30)

22.49 ± 1.17(14)

t=1.552(42)

p=0.12423

27. Accommodation half-tim

40.1 ± 0.777(30)

41.62 ± 0.998(14)

t=1.146(42)

p=0.25725

28. Hyperpol. I/V slope

0.3414 ± 0.0105(30)

0.3785 ± 0.023(13)

t=1.69(41)

p=0.09488

29. Refractoriness at 2.5m

20.2 ± 2.9(30)

22.36 ± 5.56(13)

t=0.378(41)

p=0.70729

30. TEh(20-40ms)

-91.11 ± 1.25(30)

-90.21 ± 2.15(14)

t=0.386(42)

p=0.70203

31. TEh(slope 101-140ms)

2.036 ± 0.0609(30)

2.03 ± 0.0925(14)

t=0.049(42)

p=0.91408

32. Refractoriness at 2 ms

71.69 ± 6.22(27)

64.7 ± 10(11)

t=0.599(36)

p=0.55998

33. Superexcitability at 7

-21.28 ± 0.914(30)

-20.82 ± 1.89(13)

t=0.245(41)

p=0.79433

34. Superexcitability at 5

-24.79 ± 0.879(30)

-22.94 ± 2.27(13)

t=0.925(41)

p=0.36355

35. TEd20(peak)

38.19 ± 0.525(30)

37.05 ± 1.11(14)

t=1.061(42)

p=0.29518

36. TEd40(Accom)

24.09 ± 0.527(30)

22.96 ± 1.17(14)

t=1.023(42)

p=0.31334

38. TEh(peak,-70%)

-250.1 ± 10.5(15)

-243.4 ± 8.14(12)

t=0.486(25)

p=0.63619
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iii.

Unpaired t-test: comparing control data to day 5 of lignocaine and ketamine infusion in
12 patients with chronic migraine.

Variable

Mean+/-SE(n)

Mean+/-SE(n)

t(df)

1. Stimulus (mA) for 50% m

4.287x|/1.04(30)

3.785x|/1.06(12)

t=1.864(40)

p=0.06651

3. Strength-duration\time

0.4807 ± 0.0184(30)

0.4807 ± 0.0412(12)

t=0.000(40)

p=0.9505

4. Rheobase (mA)

2.796x|/1.04(30)

2.583x|/1.07(12)

t=1.062(40)

p=0.29505

5. Stimulus-response\slope

5.128x|/1.04(30)

5.804x|/1.09(11)

t=1.397(39)

p=0.1667

6. Peak response\(mv)

8.847x|/1.06(30)

6.798x|/1.13(11)

t=2.091(39)

p=0.04084*

7. Resting I/V slope

0.6071 ± 0.0142(30)

0.5886 ± 0.0198(12)

t=0.719(40)

p=0.48286

8. Minimum I/V slope

0.2462 ± 0.008(30)

0.2364 ± 0.007(12)

t=0.726(40)

p=0.47884

9. Temperature ( C)

33.25 ± 0.17(30)

32.35 ± 0.337(12)

t=2.633(40)

p=0.01155*

10. RRP (ms)

2.953x|/1.02(30)

3.163x|/1.04(12)

t=1.662(40)

p=0.10048

11. TEh(90-100ms)

-116.7 ± 2.77(30)

-115.2 ± 4.18(12)

t=0.299(40)

p=0.75943

12. TEd(10-20ms)

68.69 ± 0.744(30)

67.15 ± 1.34(12)

t=1.067(40)

p=0.29283

13. Superexcitability (%)

-23.05 ± 0.926(30)

-21.58 ± 2.09(12)

t=0.749(40)

p=0.46437

14. Subexcitability (%)

14.4 ± 0.655(30)

15.33 ± 1.74(12)

t=0.618(40)

p=0.54739

17. Age (years)

39.1 ± 2.4(30)

37.33 ± 4.18(3)

t=0.227(31)

p=0.8064

18. Sex (M=1, F=2)

1.467 ± 0.0926(30)

1.583 ± 0.149(12)

t=0.67(40)

p=0.51348

19. Latency (ms)

6.468 ± 0.114(30)

6.525 ± 0.209(12)

t=0.256(40)

p=0.78753

20. TEd(40-60ms)

50.66 ± 0.667(30)

50.9 ± 1.3(12)

t=0.18(40)

p=0.83563

21. TEd(90-100ms)

43.96 ± 0.663(30)

42.72 ± 1.19(12)

t=0.962(40)

p=0.34439

22. TEh(10-20ms)

-73.55 ± 0.732(30)

-71.67 ± 1.47(12)

t=1.27(40)

p=0.20907

23. TEd(undershoot)

-18.78 ± 0.604(30)

-19.04 ± 1.36(12)

t=0.199(40)

p=0.82376

24. TEh(overshoot)

14.06 ± 0.597(30)

15.2 ± 1.37(12)

t=0.891(40)

p=0.38226

25. TEd(peak)

68.17 ± 0.696(30)

67.14 ± 1.46(12)

t=0.723(40)

p=0.48039

26. S2 accommodation

24.21 ± 0.528(30)

24.41 ± 1.41(12)

t=0.166(40)

p=0.84387
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p

27. Accommodation half-tim

40.1 ± 0.777(30)

42.51 ± 1.27(12)

t=1.643(40)

p=0.1043

28. Hyperpol. I/V slope

0.3414 ± 0.0105(30)

0.3426 ± 0.023(12)

t=0.054(40)

p=0.91138

29. Refractoriness at 2.5m

20.2 ± 2.9(30)

29.72 ± 7.13(12)

t=1.488(40)

p=0.14073

30. TEh(20-40ms)

-91.11 ± 1.25(30)

-88.64 ± 2.16(12)

t=1.031(40)

p=0.30988

31. TEh(slope 101-140ms)

2.036 ± 0.0609(30)

1.944 ± 0.0875(12)

t=0.821(40)

p=0.42165

32. Refractoriness at 2 ms

71.69 ± 6.22(27)

76.71 ± 16.1(9)

t=0.355(34)

p=0.72261

33. Superexcitability at 7

-21.28 ± 0.914(30)

-20.31 ± 2.28(12)

t=0.476(40)

p=0.64124

34. Superexcitability at 5

-24.79 ± 0.879(30)

-21.04 ± 2.38(12)

t=1.84(40)

p=0.06981

35. TEd20(peak)

38.19 ± 0.525(30)

37.64 ± 1.26(12)

t=0.487(40)

p=0.6337

36. TEd40(Accom)

24.09 ± 0.527(30)

24.43 ± 1.42(12)

t=0.274(40)

p=0.77579
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iv.

Unpaired t-test: comparing control data to patients with chronic migraine at 6 months
follow up after lignocaine and ketamine infusion.

Variable

Mean+/-SE(n)

Mean+/-SE(n)

t(df)

1. Stimulus (mA) for 50% m

4.287x|/1.04(30)

3.979x|/1.09(9)

t=0.932(37)

p=0.36007

3. Strength-duration\time

0.4807 ± 0.0184(30)

0.4458 ± 0.0348(9)

t=0.905(37)

p=0.37482

4. Rheobase (mA)

2.796x|/1.04(30)

2.808x|/1.13(9)

t=0.045(37)

p=0.91692

5. Stimulus-response\slope

5.128x|/1.04(30)

5.385x|/1.08(7)

t=0.498(35)

p=0.62707

6. Peak response\(mv)

8.847x|/1.06(30)

3.087x|/2.35(8)

t=2.387(36)

p=0.02128*

7. Resting I/V slope

0.6071 ± 0.0142(30)

0.5991 ± 0.0364(9)

t=0.245(37)

p=0.79455

8. Minimum I/V slope

0.2462 ± 0.008(30)

0.2457 ± 0.0105(9)

t=0.036(37)

p=0.92231

9. Temperature ( C)

33.25 ± 0.17(30)

32.23 ± 0.431(9)

t=2.623(37)

p=0.01212*

10. RRP (ms)

2.953x|/1.02(30)

3.027x|/1.07(9)

t=0.497(37)

p=0.62754

11. TEh(90-100ms)

-116.7 ± 2.77(30)

-118.2 ± 5.57(9)

t=0.248(37)

p=0.79298

12. TEd(10-20ms)

68.69 ± 0.744(30)

68.04 ± 1.39(9)

t=0.418(37)

p=0.68054

13. Superexcitability (%)

-23.05 ± 0.926(30)

-26.16 ± 2.23(9)

t=1.499(37)

p=0.13854

14. Subexcitability (%)

14.4 ± 0.655(30)

13.43 ± 1.7(9)

t=0.645(37)

p=0.53025

18. Sex (M=1, F=2)

1.467 ± 0.0926(30)

1.444 ± 0.176(9)

t=0.114(37)

p=0.87547

19. Latency (ms)

6.468 ± 0.114(30)

6.503 ± 0.182(9)

t=0.151(37)

20. TEd(40-60ms)

50.66 ± 0.667(30)

53.89 ± 0.792(9)

t=2.493(37)

p=0.01652*

21. TEd(90-100ms)

43.96 ± 0.663(30)

44.74 ± 1.46(9)

t=0.536(37)

p=0.60129

22. TEh(10-20ms)

-73.55 ± 0.732(30)

-71.22 ± 1.79(9)

t=1.414(37)

p=0.16209

23. TEd(undershoot)

-18.78 ± 0.604(30)

-18.82 ± 1.55(9)

t=0.024(37)

p=0.93007

24. TEh(overshoot)

14.06 ± 0.597(30)

14.86 ± 1.67(9)

t=0.562(37)

p=0.58403

25. TEd(peak)

68.17 ± 0.696(30)

69.09 ± 1.29(9)

t=0.631(37)

p=0.53884

26. S2 accommodation

24.21 ± 0.528(30)

24.35 ± 1.8(9)

t=0.104(37)

p=0.8814

27. Accommodation half-tim

40.1 ± 0.777(30)

44.7 ± 1.1(9)

t=2.976(37)

p=0.0051**
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p=0.85349

28. Hyperpol. I/V slope

0.3414 ± 0.0105(30)

0.3717 ± 0.0327(9)

t=1.164(37)

p=0.25076

29. Refractoriness at 2.5m

20.2 ± 2.9(30)

26.88 ± 11.4(9)

t=0.828(37)

p=0.41787

30. TEh(20-40ms)

-91.11 ± 1.25(30)

-89.32 ± 2.91(9)

t=0.647(37)

p=0.52883

31. TEh(slope 101-140ms)

2.036 ± 0.0609(30)

1.989 ± 0.107(9)

t=0.37(37)

p=0.71286

32. Refractoriness at 2 ms

71.69 ± 6.22(27)

68.58 ± 17.6(8)

t=0.21(33)

p=0.81678

33. Superexcitability at 7

-21.28 ± 0.914(30)

-25.5 ± 2.18(9)

t=2.065(37)

p=0.04364*

34. Superexcitability at 5

-24.79 ± 0.879(30)

-25.39 ± 3.3(9)

t=0.254(37)

p=0.78888

35. TEd20(peak)

38.19 ± 0.525(30)

38.99 ± 1.23(9)

t=0.685(37)

p=0.50422

36. TEd40(Accom)

24.09 ± 0.527(30)

24.27 ± 1.81(9)

t=0.128(37)

p=0.86695

Legend
* Significant
**Highly significant (temperature is a major factor in the significance of stimulus response in
baseline, day five and six month follow-up – therefore, significance mainly influenced by
operational factors, particularly temperature rather than migraine patients having heightened
stimulus sensitivity related to central sensitisation).
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